1
|
Pooh RK, Takeda M, Itoh K, Yoshimatsu J, Ogo K, Machida M, Ohashi H, Shimokawa O. Open isthmus and lambda (Λ) sign of early Joubert syndrome: elucidating development of molar tooth sign. Ultrasound Obstet Gynecol 2024. [PMID: 38642341 DOI: 10.1002/uog.27666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Revised: 03/29/2024] [Accepted: 04/03/2024] [Indexed: 04/22/2024]
Affiliation(s)
- R K Pooh
- Fetal Brain Center, CRIFM Prenatal Medical Clinic, Osaka, Japan
- Department of Clinical Research, Ritz Medical Co. Ltd., Osaka, Japan
| | - M Takeda
- Department of Clinical Research, Ritz Medical Co. Ltd., Osaka, Japan
| | - K Itoh
- Department of Diagnostic Pathology, Kyoto Chubu Medical Center, Kyoto, Japan
| | - J Yoshimatsu
- Department of Obstetrics and Gynecology, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - K Ogo
- Department of Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - M Machida
- Fetal Brain Center, CRIFM Prenatal Medical Clinic, Osaka, Japan
| | - H Ohashi
- Department of Clinical Research, Ritz Medical Co. Ltd., Osaka, Japan
| | - O Shimokawa
- Department of Clinical Research, Ritz Medical Co. Ltd., Osaka, Japan
| |
Collapse
|
2
|
Tsunoda K, Ishii T, Kuroda H, Nakatani H, Tateda M, Masuda S, Takiguchi T, Tanaka F, Misawa H, Senarita M, Takazawa M, Itoh K, Baer T. Exploring the relationship between plasma substance P and glottal incompetence in the elderly. Heliyon 2024; 10:e25751. [PMID: 38375315 PMCID: PMC10875434 DOI: 10.1016/j.heliyon.2024.e25751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Revised: 01/28/2024] [Accepted: 02/01/2024] [Indexed: 02/21/2024] Open
Abstract
We speculated that increased blood-plasma levels of Substance P may serve as an indicator of glottal incompetence, which is usually indicated by reduced maximum phonation time. We performed an initial study to test the plausibility of this hypothesis. Patients with dysphonia caused by glottal incompetence were asked to perform vocal exercises for six months to reduce glottal incompetence and we compared the plasma concentration of Substance P before and after the vocal exercise to detect correlation between maximum phonation time and plasma concentration of Substance P. Based on the results, we further hypothesized that patients exhibiting dysphonia with maximum phonation time less than 14 s, in particular less than 10 sec, caused by glottal incompetence may have increased plasma concentration of Substance P with the results of elevated thresholds of cough reflex associated with subclinical aspiration in airways. Further study is needed on patients with decreased Substance P levels, with low scores on Activities of Daily Living and who are hospitalized with aspiration pneumonia.
Collapse
Affiliation(s)
- Koichi Tsunoda
- Department of Otolaryngology, NHO (National Hospital Organization) Tokyo Medical Center, Tokyo, Japan
- Department of Artificial Organs & Medical Creations, NHO (National Hospital Organization) Tokyo Medical Center, Tokyo, Japan
| | - Toyota Ishii
- Department of Otolaryngology, NHO (National Hospital Organization) Sagamihara Hospital, Kanagawa, Japan
| | - Hiroyuki Kuroda
- Department of Otolaryngology, NHO (National Hospital Organization) Kobe Medical Center, Hyogo, Japan
| | - Hiroaki Nakatani
- Department of Otolaryngology, NHO (National Hospital Organization) Fukuyama Medical Center, Hiroshima, Japan
| | - Masaru Tateda
- Department of Otolaryngology, NHO (National Hospital Organization) Sendai Medical Center, Miyagi, Japan
| | - Sawako Masuda
- Department of Otolaryngology, NHO (National Hospital Organization) Mie Hospital, Mie, Japan
| | - Tetsuya Takiguchi
- Department of Otolaryngology, NHO (National Hospital Organization) Kanazawa Medical Center, Ishikawa, Japan
| | - Fujinobu Tanaka
- Department of Otolaryngology, NHO (National Hospital Organization) Nagasaki Medical Center, Nagasaki, Japan
| | - Hayato Misawa
- Department of Otolaryngology, NHO (National Hospital Organization) Nagoya Medical Center, Aichi, Japan
| | - Masamitsu Senarita
- Department of Otolaryngology, NHO (National Hospital Organization) Mito Medical Center, Ibaraki, Japan
| | - Mihiro Takazawa
- Department of Artificial Organs & Medical Creations, NHO (National Hospital Organization) Tokyo Medical Center, Tokyo, Japan
| | - Kenji Itoh
- Department of Artificial Organs & Medical Creations, NHO (National Hospital Organization) Tokyo Medical Center, Tokyo, Japan
| | | |
Collapse
|
3
|
Kin F, Itoh K, Bando T, Shinohara K, Oyama N, Terakado A, Yoshida M, Sumida S. Impact of avalanche type of transport on internal transport barrier formation in tokamak plasmas. Sci Rep 2023; 13:19748. [PMID: 37957265 PMCID: PMC10643559 DOI: 10.1038/s41598-023-46978-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Accepted: 11/07/2023] [Indexed: 11/15/2023] Open
Abstract
In magnetic fusion plasmas, a transport barrier is essential to improve the plasma confinement. The key physics behind the formation of a transport barrier is the suppression of the micro-scale turbulent transport. On the other hand, long-range transport events, such as avalanches, has been recognized to play significant roles for global profile formations. In this study, we observed the impact of the avalanche-type of transport on the formation of a transport barrier for the first time. The avalanches are found to inhibit the formation of the internal transport barrier (ITB) observed in JT-60U tokamak. We found that (1) ITBs do not form in the presence of avalanches but form under the disappearance of avalanches, (2) the surface integral of avalanche-driven heat fluxe is comparable to the time rate change of stored energy retained at the ITB onset, (3) the mean E × B flow shear is accelerated via the ion temperature gradient that is not sustained under the existence of avalanches, and (4) after the ITB formation, avalanches are damped inside the ITB, while they remain outside the ITB.
Collapse
Affiliation(s)
- F Kin
- National Institutes for Quantum Science and Technology, Naka, 311-0193, Japan.
- Institute of Advanced Energy, Kyoto University, Uji, 611-0011, Japan.
| | - K Itoh
- Frontier Research Institute, Chubu University, Kasugai, 487-8501, Japan
- Research Center for Plasma Turbulence, Kyushu University, Kasuga, 816-8580, Japan
| | - T Bando
- Toyohashi University of Technology, Toyohashi, 441-8580, Japan
| | - K Shinohara
- National Institutes for Quantum Science and Technology, Naka, 311-0193, Japan
- The University of Tokyo, Kashiwa, 277-8561, Japan
| | - N Oyama
- National Institutes for Quantum Science and Technology, Naka, 311-0193, Japan
| | - A Terakado
- National Institutes for Quantum Science and Technology, Naka, 311-0193, Japan
| | - M Yoshida
- National Institutes for Quantum Science and Technology, Naka, 311-0193, Japan
| | - S Sumida
- National Institutes for Quantum Science and Technology, Naka, 311-0193, Japan
| |
Collapse
|
4
|
Kawasaki A, Kusumawati PA, Kawamura Y, Kondo Y, Kusaoi M, Amano H, Kusanagi Y, Itoh K, Fujimoto T, Tamura N, Hashimoto H, Matsumoto I, Sumida T, Tsuchiya N. Genetic dissection of HLA-DRB1*15:01 and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role for HLA-DRB1*15:01. RMD Open 2023; 9:rmdopen-2023-003214. [PMID: 37258043 DOI: 10.1136/rmdopen-2023-003214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2023] [Accepted: 05/12/2023] [Indexed: 06/02/2023] Open
Abstract
OBJECTIVE Major histocompatibility complex strongly contributes to susceptibility to systemic lupus erythematosus (SLE). In the European populations, HLA-DRB1*03:01 and DRB1*15:01 are susceptibility alleles, but C4 locus was reported to account for the association of DRB1*03:01. With respect to DRB1*15:01, strong linkage disequilibrium with a variant rs2105898T in the XL9 region, located between DRB1 and DQA1 and regulates HLA-class II expression levels, was reported; however, the causative allele remains to be determined. Leveraging the genetic background of the Japanese population, where DRB1*15:01 and DRB1*15:02 are commonly present and only DRB1*15:01 is associated with SLE, this study aimed to distinguish the genetic contribution of DRB1*15:01 and XL9 variants. METHODS Among the XL9 variants, two (rs2105898 and rs9271593) previously associated variants in the European populations and two (rs9271375 and rs9271378) which showed a trend towards association in a Japanese Genome-Wide Association Study were selected. Associations of the XL9 variants and HLA-DRB1 were examined in 442 Japanese SLE patients and 779 controls. Genotyping of the XL9 variants was performed by TaqMan SNP Genotyping Assay and direct sequencing. HLA-DRB1 alleles were determined by PCR-reverse sequence-specific oligonucleotide probes. RESULTS Among the XL9 variants, associations of rs2105898T and rs9271593C were replicated in the Japanese population. However, these associations became no longer significant when conditioned on DRB1*15:01. In contrast, the association of DRB1*15:01 remained significant after conditioning on the XL9 variants. CONCLUSION In the Japanese population, HLA-DRB1*15:01 was found to be primarily associated with SLE, and to account for the apparent association of XL9 region.
Collapse
Affiliation(s)
- Aya Kawasaki
- Molecular and Genetic Epidemiology Laboratory, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
- Master's Program in Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
- College of Medical Sciences, University of Tsukuba, Tsukuba, Japan
| | - Premita Ari Kusumawati
- Molecular and Genetic Epidemiology Laboratory, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
- Master's Program in Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
| | - Yuka Kawamura
- Molecular and Genetic Epidemiology Laboratory, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
- College of Medical Sciences, University of Tsukuba, Tsukuba, Japan
| | - Yuya Kondo
- Department of Rheumatology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
| | - Makio Kusaoi
- Department of Internal Medicine and Rheumatology, Faculty of Medicine, Juntendo University, Tokyo, Japan
| | - Hirofumi Amano
- Department of Internal Medicine and Rheumatology, Faculty of Medicine, Juntendo University, Tokyo, Japan
- Department of Internal Medicine and Rheumatology, Juntendo University Nerima Hospital, Tokyo, Japan
| | - Yasuyoshi Kusanagi
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Kenji Itoh
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Takashi Fujimoto
- Department of General Medicine, Nara Medical University, Kashihara, Japan
| | - Naoto Tamura
- Department of Internal Medicine and Rheumatology, Faculty of Medicine, Juntendo University, Tokyo, Japan
| | | | - Isao Matsumoto
- Department of Rheumatology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
| | - Takayuki Sumida
- Department of Rheumatology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
| | - Naoyuki Tsuchiya
- Molecular and Genetic Epidemiology Laboratory, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
- Master's Program in Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
- College of Medical Sciences, University of Tsukuba, Tsukuba, Japan
| |
Collapse
|
5
|
Kawasaki A, Sada KE, Kusumawati PA, Hirano F, Kobayashi S, Nagasaka K, Sugihara T, Ono N, Fujimoto T, Kusaoi M, Tamura N, Kusanagi Y, Itoh K, Sumida T, Yamagata K, Hashimoto H, Makino H, Arimura Y, Harigai M, Tsuchiya N. Association of HLA-class II alleles with risk of relapse in myeloperoxidase-antineutrophil cytoplasmic antibody positive vasculitis in the Japanese population. Front Immunol 2023; 14:1119064. [PMID: 36969218 PMCID: PMC10030796 DOI: 10.3389/fimmu.2023.1119064] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Accepted: 02/23/2023] [Indexed: 03/11/2023] Open
Abstract
BackgroundDisease relapse remains a major problem in the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). In European populations, HLA-DPB1*04:01 is associated with both susceptibility and relapse risk in proteinase 3-ANCA positive AAV. In a Japanese population, we previously reported an association between HLA-DRB1*09:01 and DQB1*03:03 with susceptibility to, and DRB1*13:02 with protection from, myeloperoxidase-ANCA positive AAV (MPO-AAV). Subsequently, the association of DQA1*03:02, which is in strong linkage disequilibrium with DRB1*09:01 and DQB1*03:03, with MPO-AAV susceptibility was reported in a Chinese population. However, an association between these alleles and risk of relapse has not yet been reported. Here, we examined whether HLA-class II is associated with the risk of relapse in MPO-AAV.MethodsFirst, the association of HLA-DQA1*03:02 with susceptibility to MPO-AAV and microscopic polyangiitis (MPA) and its relationship with previously reported DRB1*09:01 and DQB1*03:03 were examined in 440 Japanese patients and 779 healthy controls. Next, the association with risk of relapse was analyzed in 199 MPO-ANCA positive, PR3-ANCA negative patients enrolled in previously reported cohort studies on remission induction therapy. Uncorrected P values (Puncorr) were corrected for multiple comparisons in each analysis using the false discovery rate method.ResultsThe association of DQA1*03:02 with susceptibility to MPO-AAV and MPA was confirmed in a Japanese population (MPO-AAV: Puncorr=5.8x10-7, odds ratio [OR] 1.74, 95% confidence interval [CI] 1.40–2.16, MPA: Puncorr=1.1x10-5, OR 1.71, 95%CI 1.34–2.17). DQA1*03:02 was in strong linkage disequilibrium with DRB1*09:01 and DQB1*03:03, and the causal allele could not be determined using conditional logistic regression analysis. Relapse-free survival was shorter with nominal significance in carriers of DRB1*09:01 (Puncorr=0.049, Q=0.42, hazard ratio [HR]:1.87), DQA1*03:02 (Puncorr=0.020, Q=0.22, HR:2.11) and DQB1*03:03 (Puncorr=0.043, Q=0.48, HR:1.91) than in non-carriers in the log-rank test. Conversely, serine carriers at position 13 of HLA-DRβ1 (HLA-DRβ1_13S), including DRB1*13:02 carriers, showed longer relapse-free survival with nominal significance (Puncorr=0.010, Q=0.42, HR:0.31). By combining DQA1*03:02 and HLA-DRβ1_13S, a significant difference was detected between groups with the highest and lowest risk for relapse (Puncorr=0.0055, Q=0.033, HR:4.02).ConclusionHLA-class II is associated not only with susceptibility to MPO-AAV but also with risk of relapse in the Japanese population.
Collapse
Affiliation(s)
- Aya Kawasaki
- Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
- Master’s Program in Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
- *Correspondence: Aya Kawasaki, ; Naoyuki Tsuchiya,
| | - Ken-ei Sada
- Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
- Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Premita Ari Kusumawati
- Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
- Master’s Program in Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
| | - Fumio Hirano
- Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
- Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Shigeto Kobayashi
- Department of Internal Medicine, Juntendo University Koshigaya Hospital, Saitama, Japan
| | - Kenji Nagasaka
- Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan
| | - Takahiko Sugihara
- Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
- Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Nobuyuki Ono
- Department of Rheumatology, Saga University, Saga, Japan
| | - Takashi Fujimoto
- Department of General Medicine, Nara Medical University, Kashihara, Japan
| | - Makio Kusaoi
- Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Naoto Tamura
- Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Yasuyoshi Kusanagi
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Kenji Itoh
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Takayuki Sumida
- Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - Kunihiro Yamagata
- Department of Nephrology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | | | | | - Yoshihiro Arimura
- Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Mitaka, Japan
- Department of Internal Medicine, Kichijoji Asahi Hospital, Musashino, Japan
| | - Masayoshi Harigai
- Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
| | - Naoyuki Tsuchiya
- Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
- Master’s Program in Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
- *Correspondence: Aya Kawasaki, ; Naoyuki Tsuchiya,
| |
Collapse
|
6
|
Hirose W, Harigai M, Amano K, Hidaka T, Itoh K, Aoki K, Nakashima M, Nagasawa H, Komano Y, Nanki T. Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis. Rheumatol Adv Pract 2022; 6:rkac090. [PMID: 36407801 PMCID: PMC9667967 DOI: 10.1093/rap/rkac090] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2022] [Accepted: 10/21/2022] [Indexed: 07/26/2023] Open
Abstract
OBJECTIVE We compared the 52-week effectiveness and safety of tofacitinib (TOF) and abatacept (ABT) in patients with RA in a real-world setting and investigated a role of human leucocyte antigens (HLA)-DRB1 shared epitope (SE) in the effectiveness. METHODS RA patients starting TOF (n = 187) and ABT (n = 183) were enrolled. Effectiveness was compared after reducing the selection bias to a minimum using the inverse probability of treatment weighting (IPTW) based on propensity scores. The influence of SE alleles on effectiveness was compared within each treatment group. A treatment group comparison was also performed within SE-positive and SE-negative groups. RESULTS Herpes zoster and some laboratory abnormalities were more frequent in the TOF group than in the ABT group. Patient characteristics did not differ significantly between treatment groups after adjustments with IPTW. The TOF group had a significantly higher proportion of DAS in 28 joints using ESR (DAS28-ESR) remission at week 52 than the ABT group. The DAS28-ESR at week 12 and thereafter was not affected by the copy number of SE alleles in the TOF group, but decreased significantly as the copy number increased in the ABT group. In SE-positive patients, remission and drug retention rates did not differ significantly between the two treatment groups. In SE-negative patients, the TOF group showed significantly higher remission and drug retention rates than the ABT group. CONCLUSION The present results suggest that TOF is more effective with regard to remission at week 52 based on treatment responses in SE-negative RA patients.
Collapse
Affiliation(s)
- Wataru Hirose
- Correspondence to: Wataru Hirose, Hirose Clinic of Rheumatology, 2-14-7 Midori-chou, Tokorozawa, Saitama 359-1111, Japan. E-mail:
| | - Masayoshi Harigai
- Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
| | - Koichi Amano
- Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
| | - Toshihiko Hidaka
- Institute of Rheumatology, Zenjinkai Miyazaki-Zenjinkai Hospital, Miyazaki, Japan
| | - Kenji Itoh
- Division of Rheumatology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | | | - Masahiro Nakashima
- Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan
| | | | - Yukiko Komano
- Division of Rheumatology, Department of Internal Medicine, Jujo Takeda Rehabilitation Hospital, Kyoto, Japan
| | - Toshihiro Nanki
- Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
| |
Collapse
|
7
|
Kudo H, Miyata C, Kawaguchi Y, Yachi Y, Shinfuku M, Kinoshita T, Kurihara T, Momiyama Y, Chong T, Kobayashi Y, Takazawa M, Itoh K, Tsunoda K. Do Hospital Visit Restrictions Cause Increase in the Doses of Morphine in Terminal Care? Spiritual Pain and Palliative Care in the COVID-19 Pandemic. Am J Med 2022; 135:1156-1157. [PMID: 35476915 PMCID: PMC9040511 DOI: 10.1016/j.amjmed.2022.04.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Revised: 03/30/2022] [Accepted: 04/03/2022] [Indexed: 12/15/2022]
Affiliation(s)
- Hiroshi Kudo
- Palliative Care Team, COVID-19 Solution Team, and Clinical Research Center of National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Chieko Miyata
- Palliative Care Team, COVID-19 Solution Team, and Clinical Research Center of National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Yoshiki Kawaguchi
- Palliative Care Team, COVID-19 Solution Team, and Clinical Research Center of National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Yutaka Yachi
- Palliative Care Team, COVID-19 Solution Team, and Clinical Research Center of National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Masaki Shinfuku
- Palliative Care Team, COVID-19 Solution Team, and Clinical Research Center of National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Takayuki Kinoshita
- Palliative Care Team, COVID-19 Solution Team, and Clinical Research Center of National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Tomohiro Kurihara
- Palliative Care Team, COVID-19 Solution Team, and Clinical Research Center of National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Yukihiko Momiyama
- Palliative Care Team, COVID-19 Solution Team, and Clinical Research Center of National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Tonghyo Chong
- Palliative Care Team, COVID-19 Solution Team, and Clinical Research Center of National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Yoshiro Kobayashi
- Palliative Care Team, COVID-19 Solution Team, and Clinical Research Center of National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Mihiro Takazawa
- Palliative Care Team, COVID-19 Solution Team, and Clinical Research Center of National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Kenji Itoh
- Palliative Care Team, COVID-19 Solution Team, and Clinical Research Center of National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Koichi Tsunoda
- Palliative Care Team, COVID-19 Solution Team, and Clinical Research Center of National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
| |
Collapse
|
8
|
Hayashi N, Ogasawara D, Tokorodani R, Kirizume R, Kenda S, Yabe F, Itoh K. What factors influence the R value in data-driven respiratory gating technique? A phantom study. Nucl Med Commun 2022; 43:1067-1076. [PMID: 36081398 DOI: 10.1097/mnm.0000000000001609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE The R value is adopted as a metric for the effectiveness of the respiratory waveform in the Advanced Motion Free implemented in the PET scanner as the data-driven respiratory gating (DDG) algorithm. The effects of changes in various factors on R values were evaluated by phantom analysis. METHODS We used a programmable respiratory motion phantom QUASAR with a sphere filled with an 18F solution. Respiratory motion simulation was performed by changing the sphere diameter, radioactivity concentration, amplitude, respiratory cycle, and respiratory waveform shape. Three evaluations were performed. (1) The power spectra calculated from the input waveforms were evaluated. (2) The effects of changes in the factors on the R value were evaluated. (3) DDG waveforms and inspiratory peak intervals were compared with the input waveform data set. RESULTS The R values were increased and converged to a certain value as sphere diameter, radioactivity concentration, and amplitude gradually increased. The respiratory cycle showed the highest R value at 7.5 s, and the graph showed an upward convex pattern. The R value of the sinusoid waveform was higher than that of the typical waveform. There was a relationship between the power spectrum of the input waveform and R value. The visual score was also lower in the condition with a lower R value. In cases of no sphere, radioactivity, or motion, and a fast respiratory cycle, peak intervals were not accurately acquired. CONCLUSIONS Factors affecting the R value were sphere diameter, radioactivity concentration, amplitude, respiratory cycle, and respiratory waveform shape.
Collapse
Affiliation(s)
- Naoya Hayashi
- Division of Radiology, Department of Medical Technology, Kochi Medical School Hospital, Nankoku, Kochi, Japan
| | | | | | | | | | | | | |
Collapse
|
9
|
Horiuchi Y, Hashimoto K, Horikoshi H, Sano A, Kawamura Y, Fujita N, Kimata M, Ono Y, Obuchi Y, Makino A, Kaneko M, Kimura F, Itoh K, Tanaka Y. Fulminant elderly adult-onset Still disease effectively treated with tocilizumab and methotrexate: A case report. Medicine (Baltimore) 2022; 101:e29354. [PMID: 35839054 DOI: 10.1097/md.0000000000029354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
RATIONALE Adult-onset Still disease (AOSD) is a rare inflammatory disease of unknown etiology. AOSD is common in young or middle-aged adults; however, in recent years, there have been increasing reports of elderly AOSD. Differentiating AOSD from diseases such as infections and malignancies is difficult. Moreover, rare fulminant AOSD cases with resistance to corticosteroids and immunosuppressive drugs have been reported. PATIENT CONCERNS An 80-year-old woman presented with flaccid fever, generalized arthralgia, and erythema of the anterior chest for 2 weeks. On day 5 of hospitalization, the patient developed pleural effusion with hypoxemia and her vital signs indicated rapid progression to shock. During the clinical course, the levels of inflammatory markers, including maximum level of ferritin and white blood cells (WBCs) were elevated (252,796 ng/mL and 86,500/μV, respectively) with disseminated intravascular coagulation syndrome (DIC) and macrophage activation syndrome (MAS). DIAGNOSIS The patient was diagnosed with elderly AOSD as per the Yamaguchi criteria for AOSD. The state of disease was extremely severe with rapid progression and was, thus, categorized as a fulminant form of elderly AOSD. INTERVENTIONS The patient was treated with prednisolone (PSL) pulse therapy (1000 mg/d) twice and plasma exchange in the intensive care unit for the primary disease and shock. Although she recovered from shock, she developed DIC and MAS. Methotrexate (MTX; 10 mg/d) improved the DIC and MAS. However, severe pleuritis recurred and the patient developed pericarditis; her primary disease was poorly controlled. Finally, tocilizumab (TCZ) was introduced using interleukin-18 (IL-18) as a surrogate marker. The IL-18 level was measured repeatedly following admission, with the peak level (170,000 pg/mL) recorded on the 75th day of hospitalization, immediately prior to introducing TCZ. OUTCOMES The combined use of MTX, TCZ, and PSL was effective in suppressing elderly AOSD, which was unsuccessfully controlled with MTX and PSL. Frequent monitoring of IL-18 levels proved useful for differentiating elderly AOSD from other diseases. LESSONS A fulminant form of elderly AOSD was treated with a combination of MTX, TCZ, and PSL. Repeated monitoring of IL-18 levels can be useful for decision-making in treating elderly AOSD.
Collapse
Affiliation(s)
- Yugo Horiuchi
- Department of General Medicine, National Defense Medical College, Tokorozawa, Saitama
| | - Kenichi Hashimoto
- Department of General Medicine, National Defense Medical College, Tokorozawa, Saitama
| | - Hideyuki Horikoshi
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama
| | - Azusa Sano
- Department of General Medicine, National Defense Medical College, Tokorozawa, Saitama
| | - Yusuke Kawamura
- Department of General Medicine, National Defense Medical College, Tokorozawa, Saitama
- Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Saitama
| | - Naoya Fujita
- Department of General Medicine, National Defense Medical College, Tokorozawa, Saitama
| | - Motohiro Kimata
- Department of General Medicine, National Defense Medical College, Tokorozawa, Saitama
| | - Yosuke Ono
- Department of General Medicine, National Defense Medical College, Tokorozawa, Saitama
| | - Yasuhiro Obuchi
- Department of General Medicine, National Defense Medical College, Tokorozawa, Saitama
| | - Arisa Makino
- Department of Traumatology and Critical Care Medicine, National Defense Medical College, Tokorozawa, Saitama
| | - Mayuko Kaneko
- Department of Traumatology and Critical Care Medicine, National Defense Medical College, Tokorozawa, Saitama
| | - Fumihiko Kimura
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama
| | - Kenji Itoh
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama
| | - Yuji Tanaka
- Department of General Medicine, National Defense Medical College, Tokorozawa, Saitama
| |
Collapse
|
10
|
Sasaki H, Miyata J, Suematsu R, Kimizuka Y, Fujikura Y, Kichikawa Y, Sugiura H, Itoh K, Kawana A. Radiological significance of mediastinal lymphadenopathy in eosinophilic granulomatosis with polyangiitis. Allergol Int 2022; 71:536-538. [PMID: 35717376 DOI: 10.1016/j.alit.2022.05.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Revised: 05/03/2022] [Accepted: 05/16/2022] [Indexed: 11/01/2022] Open
Affiliation(s)
- Hisashi Sasaki
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan; Department of Internal Medicine, Japan Self-Defense Forces Central Hospital, Tokyo, Japan
| | - Jun Miyata
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
| | - Ryohei Suematsu
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Yoshifumi Kimizuka
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Yuji Fujikura
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | | | - Hiroaki Sugiura
- Department of Radiology, National Defense Medical College, Saitama, Japan
| | - Kenji Itoh
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Akihiko Kawana
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| |
Collapse
|
11
|
Takamatsu K, Kusanagi Y, Horikoshi H, Nakanishi T, Wada A, Koumoto S, Katsurada Y, Tsuda H, Hokari R, Kimura F, Itoh K. Acute Pancreatitis Coincided with Multiple Arteriolar Aneurysms in a Patient with Polyarteritis Nodosa. Mod Rheumatol Case Rep 2021; 6:234-238. [PMID: 34878139 DOI: 10.1093/mrcr/rxab052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Revised: 10/20/2021] [Accepted: 11/20/2021] [Indexed: 11/12/2022]
Abstract
A 78-year-old man presented to our hospital with a history of 10kg weight loss within 6 months previously, and general fatigue and fever for 2 and 1 months, respectively. On hospitalization, the patient was diagnosed with polyarteritis nodosa after multiple microaneurysms were observed in the liver, kidney, pancreas, and mesenteries. He achieved remission with the administration of 1,000mg methylprednisolone for 3 days, followed by prednisolone (55mg/day). Steroids were successfully tapered with no re-elevation in inflammation. Two months after the administration of steroids, the patient complained of acute abdominal pain, and developed severe acute pancreatitis. During treatment for pancreatitis, the patient died due to septic shock and disseminated intravascular coagulation. An autopsy revealed necrotizing vasculitis in the intrapancreatic arteries and ischemia of the downstream arterioles resulting in acute pancreatitis.
Collapse
Affiliation(s)
- Ko Takamatsu
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Yasuyoshi Kusanagi
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Hideyuki Horikoshi
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Takashi Nakanishi
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Akinori Wada
- Division of Gastroenterology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Shunsuke Koumoto
- Division of Gastroenterology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Yuka Katsurada
- Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Hitoshi Tsuda
- Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Ryota Hokari
- Division of Gastroenterology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Fumihiko Kimura
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Kenji Itoh
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| |
Collapse
|
12
|
Hirose W, Harigai M, Amano K, Hidaka T, Itoh K, Aoki K, Nakashima M, Nagasawa H, Komano Y, Nanki T. Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis. Arthritis Res Ther 2021; 23:228. [PMID: 34465391 PMCID: PMC8407060 DOI: 10.1186/s13075-021-02612-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Accepted: 08/20/2021] [Indexed: 12/15/2022] Open
Abstract
Objectives The aim of this study was to compare the clinical effectiveness of tofacitinib and abatacept and clarify the impact of the HLA-DRB1 shared epitope (SE) on responses to these treatments in patients with rheumatoid arthritis (RA). Methods After adjustments by propensity score matching, 70 out of 161 patients receiving tofacitinib and 70 out of 131 receiving abatacept were extracted. The clinical effectiveness of both drugs over 24 weeks and the impact of the copy numbers of SE on effectiveness outcomes were investigated. Results The percentage of patients in remission in the 28-joint count disease activity score using the erythrocyte sedimentation rate (DAS28-ESR) did not significantly differ between patients receiving tofacitinib and abatacept at week 24 (32% vs 37%, p = 0.359). The mean change at week 4 in DAS28-ESR from baseline was significantly greater in patients receiving tofacitinib than in those receiving abatacept (− 1.516 vs − 0.827, p = 0.0003). The percentage of patients in remission at week 4 was 30% with tofacitinib and 15% with abatacept (p = 0.016). When patients were stratified by the copy numbers of SE alleles, differences in these numbers did not affect DAS28-ESR scores of patients receiving tofacitinib. However, among patients receiving abatacept, DAS28-ESR scores were significantly lower in patients carrying 2 copies of SE alleles than in those carrying 0 copies at each time point throughout the 24-week period. Furthermore, the percentage of patients in remission with DAS28-ESR at week 24 was not affected by the copy numbers of SE alleles in patients receiving tofacitinib (p = 0.947), whereas it significantly increased as the copy numbers became higher in patients receiving abatacept (p = 0.00309). Multivariable logistic regression analyses showed a correlation between the presence of SE and DAS28-ESR remission in patients receiving abatacept (OR = 25.881, 95% CI = 3.140–213.351, p = 0.0025), but not in those receiving tofacitinib (OR = 1.473, 95% CI = 0.291–7.446, p = 0.639). Conclusions Although the clinical effectiveness of tofacitinib and abatacept was similar at week 24, tofacitinib was superior to abatacept for changes from baseline in DAS28-ESR and the achievement of remission at week 4. SE positivity was associated with the achievement of DAS28-ESR remission by week 24 in patients receiving abatacept, but not in those receiving tofacitinib. Supplementary Information The online version contains supplementary material available at 10.1186/s13075-021-02612-w.
Collapse
Affiliation(s)
- Wataru Hirose
- Hirose Clinic of Rheumatology, 2-14-7 Midori-chou, Tokorozawa, Saitama, 359-1111, Japan.
| | - Masayoshi Harigai
- Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - Koichi Amano
- Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
| | - Toshihiko Hidaka
- Institute of Rheumatology, Zenjinkai Shimin no mori Hospital, Miyazaki city, Miyazaki, Japan
| | - Kenji Itoh
- Division of Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Kazutoshi Aoki
- Aoki Clinic of Rheumatology, Saitama city, Saitama, Japan
| | - Masahiro Nakashima
- Department of Immunology and Microbiology, National Defense Medical College, Tokorozawa, Saitama, Japan
| | | | - Yukiko Komano
- Division of Rheumatology, Department of Internal Medicine, Jujo Takeda Rehabilitation Hospital, Minami-ku, Kyoto, Japan
| | - Toshihiro Nanki
- Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Tokyo, Japan
| | | |
Collapse
|
13
|
Itoh K, Yamada R, Saida J, Ikeda K, Otomo T. Atomic-level characterization of free volume in the structure of Cu 67Zr 33amorphous alloy. J Phys Condens Matter 2021; 33:274001. [PMID: 33906162 DOI: 10.1088/1361-648x/abfc12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Accepted: 04/27/2021] [Indexed: 06/12/2023]
Abstract
The structure of Cu67Zr33amorphous alloy was investigated in terms of packing density and free volume by using neutron, x-ray diffraction and reverse Monte Carlo (RMC) modelling. The RMC model was analysed by a method of decomposing the three-dimensional atomic configuration into fundamental polyhedral units (termed as 'holes' referencing the Bernal's works) of which faces are all triangles consisting of chemical bonds. Not only tetrahedral and octahedral holes but also other larger holes were identified. Moreover, the atomic packing fractions and free volumes in the respective polyhedral holes were evaluated with reference to those for the corresponding crystal structures. The results show that the distribution of free volumes for the larger holes can be described by the exponential function assuming that there are no energetic interactions between each other. On the other hand, the local structural fluctuations due to densely and loosely packed tetrahedral holes were observed, leading to the negative free volume spaces.
Collapse
Affiliation(s)
- K Itoh
- Graduate School of Education, Okayama University, 3-1-1 Tsushima-Naka, kita-ku, Okayama 700-8530, Japan
| | - R Yamada
- Frontier Research Institute for Interdisciplinary Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan
| | - J Saida
- Frontier Research Institute for Interdisciplinary Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan
| | - K Ikeda
- Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Otomo
- Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| |
Collapse
|
14
|
Gu X, Itoh K. Organizational climate for safe and effective inter-unit handoffs in Japanese hospitals. Int J Health Plann Manage 2021; 36:1153-1165. [PMID: 33797114 DOI: 10.1002/hpm.3162] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Revised: 11/17/2020] [Accepted: 03/15/2021] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVES To extract the organizational climate factors that contribute to safe and effective inter-unit patient handoffs, as well as to capture their crucial characteristics in the context of current Japanese hospitals. METHODS A questionnaire survey was conducted among nursing staff in 31 general hospitals, collecting a total of 5117 valid responses (69% response rate). RESULTS A five-factor model was established to determine the inter-unit handoff climate within hospitals. This comprised information and responsibility-related risk, role understanding, communication, handoff environment, and guidelines and process. Based on nursing staff perceptions, the inter-unit handoff climate in Japanese hospitals were generally found to be moderate or moderate-to-high levels across all five of the factors. Nursing staff's perceptions of all five climate factors differed significantly across hospitals and work units, rather than working conditions (full-time vs. part-time) or professions (nurse vs. nurse assistant). All five handoff factors were verified their significant impacts on patient safety awareness and handoff quality. Furthermore, in hospitals where staff perceptions of handoff climate were more positive, information was transferred more effectively. CONCLUSIONS An inter-unit handoff climate structure was extracted and verified its impact on handoff quality and safety. Due to moderate climate levels in Japanese hospitals, as well as background factors such as low risk awareness among staff and busy situations, promoting a more positive organizational culture is suggested for creating safer and more effective inter-unit handoffs. Improving the current handoff guidelines and processes in hospitals and using non-licensed assistive staff more effectively are also recommended.
Collapse
Affiliation(s)
- Xiuzhu Gu
- Department of Industrial Engineering and Economics, School of Engineering, Tokyo Institute of Technology, Tokyo, Japan
| | - Kenji Itoh
- Department of Industrial Engineering and Economics, School of Engineering, Tokyo Institute of Technology, Tokyo, Japan
| |
Collapse
|
15
|
Hamido S, Hamamoto R, Gu X, Itoh K. Factors influencing occupational truck driver safety in ageing society. Accid Anal Prev 2021; 150:105922. [PMID: 33338909 DOI: 10.1016/j.aap.2020.105922] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 11/13/2020] [Accepted: 11/24/2020] [Indexed: 06/12/2023]
Abstract
In ageing societies, the effective employment of ageing occupational drivers is one of the most important managerial concerns to be addressed to compensate for the lack of younger workers. In this study, the key factors contributing to the safety outcome in trucking transportation were identified using empirical data, including driving accident information, individual attributes, and task-related attributes. For this purpose, 306 driver records from 26 trucking companies in Japan were analysed. The driver sample was dichotomised by age into elderly drivers (age ≥ 50 years, referred to as older; N = 131) and young drivers (age < 50 years, referred to as younger; N = 175). Based on the analysis results, no significant age difference was identified in the likelihood of involvement in accidents for truck drivers. While older drivers who have penalty point records were more likely to be involved in traffic accidents, they were less affected by hard work conditions compared with young drivers. In conclusion, elderly drivers can be effectively employed as occupational drivers. They do not necessarily have a higher risk of accidents than young drivers. In addition, employment policies are proposed from a safety viewpoint, particularly for elderly truck drivers.
Collapse
Affiliation(s)
- Sahar Hamido
- Tokyo Institute of Technology, Department of Industrial Engineering and Economics, School of Engineering, 2-12-1 Oh-okayama, Meguro-ku, Tokyo 152-8552, Japan.
| | - Ryota Hamamoto
- Tokyo Institute of Technology, Department of Industrial Engineering and Economics, School of Engineering, 2-12-1 Oh-okayama, Meguro-ku, Tokyo 152-8552, Japan
| | - Xiuzhu Gu
- Tokyo Institute of Technology, Department of Industrial Engineering and Economics, School of Engineering, 2-12-1 Oh-okayama, Meguro-ku, Tokyo 152-8552, Japan
| | - Kenji Itoh
- Tokyo Institute of Technology, Department of Industrial Engineering and Economics, School of Engineering, 2-12-1 Oh-okayama, Meguro-ku, Tokyo 152-8552, Japan
| |
Collapse
|
16
|
Shibutani S, Yonekura M, Nosaka M, Kawamura Y, Hanada K, Kasai S, Yokota T, Higuma T, Itoh K, Tomita H. Characterizing genetic variants for DAG and IP3 signalling pathways in severe cases of coronary spastic angina. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
We previously reported that the activity of phospholipase C (PLC), a key molecule for intracellular calcium signaling, was enhanced in patients with coronary spastic angina (CSA). Furthermore, we found PLC-δ1 864 G to A mutation in about 10% of the male CSA patients. However, comprehensive understanding of genetic role in the pathogenesis of CSA remains to be elucidated.
Purpose
We tested the hypothesis that variants in the genes responsible for contraction signaling, especially a Ca2+-dependent mechanism, plays an important role in the pathogenesis of CSA.
Methods and results
Exome sequencing was performed to genotype comprehensively CSA cohort, enabling investigation of 258 gene network for diacylglycerol (DAG) and inositol trisphosphate (IP3) signallings, which are responsible for contraction signaling in the vascular smooth muscle cell (VSMC) by a Ca2+-dependent mechanism.
The study population included 30 Japanese patients with severe cases of CSA (18 men and 12 women with a mean age of 62.2±10.1 years). In 23 patients, ST segment elevation was recorded on the electrocardiogram during a spontaneous attack. In other 3 patients, ventricular fibrillation occurred following CSA attacks. The rests were diagnosed by ECG changes and elevated cardiac enzymes following CSA attacks. Genetic information from these CSA patients were compared with those from 914 healthy controls.
Frequencies of 17 common, functional polymorphisms of DAG and IP3 signallings were statistically similar to those of healthy controls. By high-quality (Call Quality ≥20, Read Depth ≥10), and predicted-deleterious (CADD score ≥20) filterings, the number of the candidate genes were narrowed from 234,445 to 17,738, and by selecting genes for DAG and IP3 signallings, further narrowed to 208 genes. Compared with 914 healthy controls, DAG and IP3 signalling genes revealed 26 variants in 15 genes in CSA cases, and by further filtering for rare (914 healthy control frequency <1%), 21 variants in 12 genes were found. They shared variants in G protein subunit alpha q (GNAQ), phospholipase C beta 3 (PLCB3), inositol 1,4,5-trisphosphate receptor type 3 (ITPR3), glutamate ionotropic receptor NMDA type subunit 2D (GRIN2D) in ≥5 cases. By filtering for high-quality, predicted-deleterious, and rare, genetic variants related with DAG and IP3 signalling were more found in severe CSA patients compared with healthy controls (CSA 4.33/person vs healthy controls 2.60 /person).
Conclusions
These findings indicate genetic heterogeneity in CSA susceptibility and a likely polygenic basis, giving a cumulative effect on DAG and IP3 signalling pathways in a subset of individual CSA patients. Study of larger cohorts is warranted to define genetic risk factors for CSA.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- S Shibutani
- Hirosaki University Graduate School of Medicine, Hirosaki, Japan
| | - M Yonekura
- Hirosaki University Graduate School of Medicine, Hirosaki, Japan
| | - M Nosaka
- Hirosaki University Graduate School of Medicine, Hirosaki, Japan
| | - Y Kawamura
- Hirosaki University Graduate School of Medicine, Hirosaki, Japan
| | - K Hanada
- Hirosaki University Graduate School of Medicine, Hirosaki, Japan
| | - S Kasai
- Hirosaki University, Stress Response Science, Hirosaki, Japan
| | - T Yokota
- Hirosaki University Graduate School of Medicine, Hirosaki, Japan
| | - T Higuma
- St. Marianna University School of Medicine, Cardiology, Kawasaki, Japan
| | - K Itoh
- Hirosaki University, Stress Response Science, Hirosaki, Japan
| | - H Tomita
- Hirosaki University Graduate School of Medicine, Hirosaki, Japan
| |
Collapse
|
17
|
Gu X, Itoh K. Inter‐shift handoff: Changes over a 6‐year interval. J Adv Nurs 2020; 76:3418-3428. [DOI: 10.1111/jan.14537] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2020] [Revised: 06/29/2020] [Accepted: 07/24/2020] [Indexed: 11/27/2022]
Affiliation(s)
- Xiuzhu Gu
- Department of Industrial Engineering and Economics School of Engineering Tokyo Institute of Technology Meguro‐ku Tokyo Japan
| | - Kenji Itoh
- Department of Industrial Engineering and Economics School of Engineering Tokyo Institute of Technology Meguro‐ku Tokyo Japan
| |
Collapse
|
18
|
Takada K, Katada Y, Ito S, Hayashi T, Kishi J, Itoh K, Yamashita H, Hirakata M, Kawahata K, Kawakami A, Watanabe N, Atsumi T, Takasaki Y, Miyasaka N. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Rheumatology (Oxford) 2020; 59:1084-1093. [PMID: 31539061 PMCID: PMC7850120 DOI: 10.1093/rheumatology/kez394] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Revised: 07/19/2019] [Indexed: 12/19/2022] Open
Abstract
Objective Interstitial pneumonia is common and has high short-term mortality in patients with PM and DM despite glucocorticoid (GC) treatment. Retrospective studies suggested that the early use of immunosuppressive drugs with GCs might improve its short-term mortality. Methods A multicentre, single-arm, 52-week-long clinical trial was performed to test whether the initial combination treatment with tacrolimus (0.075 mg/kg/day, adjusted for the target whole-blood trough levels between 5 and 10 ng/ml) and GCs (0.6–1.0 mg/kg/day of prednisolone followed by a slow taper) improves short-term mortality of PM/DM-interstitial pneumonia patients. The primary outcome was overall survival. We originally intended to compare, by using propensity-score matching, the outcome data of clinical trial patients with that of historical control patients who were initially treated with GCs alone. Results The 52-week survival rate with the combination treatment (N = 26) was 88.0% (95% CI, 67.3, 96.0). Safety profiles of the combination treatment were consistent with those known for tacrolimus and high-dose GCs individually. Serious adverse events occurred in 11 patients (44.0%), which included four opportunistic infections. Only 16 patients, including only 1 deceased patient, were registered as historical controls, which precluded meaningful comparative analysis against the clinical trial patients. Conclusion Our study provided findings which suggest that initial treatment with tacrolimus and GCs may improve short-term mortality of PM/DM-interstitial pneumonia patients with manageable safety profiles. This was the first prospective clinical investigation conducted according to the Good Clinical Practice Guideline of the International Conference on Harmonization for the treatment of this potentially life-threatening disease. Trial registration ClinicalTrials.gov, http://clinicaltrials.gov, NCT00504348.
Collapse
Affiliation(s)
- Kazuki Takada
- Department of Professional Development in Health Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo
| | - Yoshinori Katada
- Department of Rheumatology and Clinical Immunology, Sakai City Medical Center, Osaka
| | - Satoshi Ito
- Department of Rheumatology, Niigata Rheumatic Center, Niigata
| | - Taichi Hayashi
- Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki
| | - Jun Kishi
- Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima
| | - Kenji Itoh
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Saitama
| | - Hiroyuki Yamashita
- Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo
| | - Michito Hirakata
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo
| | - Kimito Kawahata
- Division of Rheumatology and Allergology, Department of Internal Medicine, St Marianna University School of Medicine, Kanagawa
| | - Atsushi Kawakami
- Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki
| | - Norihiko Watanabe
- Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba
| | - Tatsuya Atsumi
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Hokkaido
| | - Yoshinari Takasaki
- Department of Internal Medicine, Juntendo University Koshigaya Hospital, Saitama
| | - Nobuyuki Miyasaka
- Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| |
Collapse
|
19
|
Horikoshi H, Nakanishi T, Tamura K, Kimura F, Itoh K. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography for the diagnosis of polymyalgia-like illnesses: a retrospective study. BMC Rheumatol 2020; 4:21. [PMID: 32346670 PMCID: PMC7181584 DOI: 10.1186/s41927-020-00121-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Accepted: 02/13/2020] [Indexed: 11/10/2022] Open
Abstract
Background Various inflammatory conditions may present with musculoskeletal symptoms similar to those of polymyalgia rheumatica (PMR). We investigated findings on 18F-fluorodexoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) images that may differentiate PMR from polymyalgia-like illnesses. Methods We analyzed data from 25 patients with new-onset polymyalgia-like illnesses who fulfilled Bird's diagnostic criteria for PMR and had undergone FDG-PET/CT scan. To assess the uptake by major joints and synovial bursae, particularly at PMR-specific sites (shoulder, sternoclavicular, and hip joints, interspinous bursae, ischial tuberosities, and greater trochanters), we used visual scoring system to score FDG uptake: 0, no uptake (same as bone); 1, slight uptake; 2, moderate uptake (same as the liver); 3, greater uptake than the liver; and 4, uptake as strong as in the cerebellum. Results The final diagnoses were PMR in 17 patients and non-PMR in eight patients (three malignancies, two infections, one cholesterol crystal embolism, one ANCA-associated vasculitis, and one undefined diagnosis). Although the serum MMP-3 levels were significantly higher in patients with PMR, C-reactive protein and erythrocyte sedimentation rate mean values did not differ between the two groups. In PMR-specific sites, FDG accumulations were observed in all cases of PMR, with a high PET-positive score of 2.00 (range, 0-3), but it was low in non-PMR cases, with a PET-positive score of 1.00 (range, 0-3). Conclusions The FDG accumulation patterns in polymyalgia-like illness differ from those in PMR, despite the similar clinical presentations of both conditions. An FDG-PET/CT scan is useful for differentiating PMR from other polymyalgia-like illnesses.
Collapse
Affiliation(s)
- Hideyuki Horikoshi
- 1Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513 Japan
| | - Takashi Nakanishi
- 1Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513 Japan
| | - Katsumi Tamura
- Tokorozawa PET Diagnostic Imaging Clinic, 7-5 Higashi Sumiyoshi, Tokorozawa, Saitama, 359-1124 Japan
| | - Fumihiko Kimura
- 1Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513 Japan
| | - Kenji Itoh
- 1Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513 Japan
| |
Collapse
|
20
|
Nakamura D, Kimura T, Itoh K, Fujimoto N, Nitta S, Amano H. Tungsten carbide layers deposited on graphite substrates via a wet powder process as anti-parasitic-reaction coatings for reactor components in GaN growth. CrystEngComm 2020. [DOI: 10.1039/c9ce01971e] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Catalytic tungsten carbide coatings provide multi-functional (w/ anti-parasitic-reaction and protective functions) reactor components for growth of large GaN crystals.
Collapse
Affiliation(s)
| | | | - Kenji Itoh
- Toyota Central R&D Labs., Inc
- Nagakute
- Japan
| | - Naoki Fujimoto
- Institute of Materials and Systems for Sustainability
- Nagoya Univ
- Nagoya 464-8601
- Japan
| | - Shugo Nitta
- Institute of Materials and Systems for Sustainability
- Nagoya Univ
- Nagoya 464-8601
- Japan
| | - Hiroshi Amano
- Institute of Materials and Systems for Sustainability
- Nagoya Univ
- Nagoya 464-8601
- Japan
| |
Collapse
|
21
|
Gu X, Itoh K. A comparative study on healthcare employee satisfaction between Japan and China. Int J Health Plann Manage 2020; 35:171-184. [DOI: 10.1002/hpm.2859] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2019] [Revised: 07/10/2019] [Accepted: 07/10/2019] [Indexed: 11/10/2022] Open
Affiliation(s)
- Xiuzhu Gu
- Department of Industrial Engineering and Economics, School of EngineeringTokyo Institute of Technology Tokyo Japan
| | - Kenji Itoh
- Department of Industrial Engineering and Economics, School of EngineeringTokyo Institute of Technology Tokyo Japan
| |
Collapse
|
22
|
Oka Y, Takata N, Itoh K. Sleep habit and internet use among Japanese preschoolers. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Oka Y, Itoh K, Norimi T. Sleep habit and internet use of preschoolers. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Suekane S, Noguchi M, Terasaki M, Yutani S, Narita Y, Yamada A, Shichijo S, Igawa T, Itoh K. Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz239.048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Yoshiyama K, Noguchi M, Terasaki M, Sugawara S, Yamada A, Shichijo S, Takamori S, Akagi Y, Yutani S, Itoh K. P2.04-65 Peptide-Based Cancer Vaccine Shortened the Overall Survival of a Large Portion, but Not All, of Advanced Cancer Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
26
|
Pooh RK, Machida M, Nakamura T, Uenishi K, Chiyo H, Itoh K, Yoshimatsu J, Ueda H, Ogo K, Chaemsaithong P, Poon LC. Increased Sylvian fissure angle as early sonographic sign of malformation of cortical development. Ultrasound Obstet Gynecol 2019; 54:199-206. [PMID: 30381845 PMCID: PMC6772089 DOI: 10.1002/uog.20171] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Revised: 10/17/2018] [Accepted: 10/19/2018] [Indexed: 05/20/2023]
Abstract
OBJECTIVE To evaluate Sylvian fissure development by assessing Sylvian fissure angles in fetuses with malformation of cortical development (MCD). METHODS This was a retrospective study of 22 fetuses with MCD. Cases with a stored three-dimensional (3D) brain volume acquired at 18 + 0 to 30 + 6 weeks of gestation at an ultrasound-based research clinic between January 2010 and December 2017 were identified through a database. Of the 22 fetuses, seven had an extracranial abnormality, such as cardiac, renal, gastrointestinal and/or digital anomalies, and five had a minor abnormality such as micrognathia, low-set ears and/or single umbilical artery. To confirm the final clinical diagnosis of brain abnormality, postmortem histological findings or prenatal or postnatal magnetic resonance images were used. For measurement of Sylvian fissure angle, an anterior coronal plane of the fetal brain on transvaginal 3D volume multiplanar imaging was visualized as a single image from the three orthogonal views. The right and left Sylvian fissure angles were measured between a horizontal reference line (0°) and a line drawn along the upper side of the respective Sylvian fissure. The Sylvian fissure angle on both sides was plotted on the graphs of the reference ranges for gestational age in weeks. RESULTS In 21 (95.5%; 95% CI, 86.8-100.0%) of 22 fetuses with MCD, the Sylvian fissure angle on one or both sides was larger than the 90th percentile of the normal reference. There was one case with apparent focal MCD in the parietal lobe, but the Sylvian fissure angles were normal. A case with apparent unilateral cortical dysplasia and one with apparent unilateral schizencephaly had conspicuous discrepancies between the left and right Sylvian fissure angles. Abnormal genetic test results were obtained in six cases, including four cases with a mutation in a single gene. CONCLUSIONS This study has shown that the Sylvian fissures, as defined by the Sylvian fissure angle, have delayed development in most MCD cases prior to the diagnosis of the condition. The Sylvian fissure angle may potentially be a strong indicator for the subsequent development of cortical malformation, before the time point at which the gyri and sulci become obvious on the fetal brain surface. Further research is required to validate these findings. © 2018 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
Collapse
Affiliation(s)
- R. K. Pooh
- CRIFM Clinical Research Institute of Fetal Medicine Pooh Maternity ClinicOsakaJapan
| | - M. Machida
- CRIFM Clinical Research Institute of Fetal Medicine Pooh Maternity ClinicOsakaJapan
| | - T. Nakamura
- CRIFM Clinical Research Institute of Fetal Medicine Pooh Maternity ClinicOsakaJapan
| | - K. Uenishi
- CRIFM Clinical Research Institute of Fetal Medicine Pooh Maternity ClinicOsakaJapan
| | - H. Chiyo
- CRIFM Clinical Research Institute of Fetal Medicine Pooh Maternity ClinicOsakaJapan
| | - K. Itoh
- Department of Pathology and Applied Neurobiology, Graduate School of Medical ScienceKyoto Prefectural University of MedicineKyotoJapan
| | - J. Yoshimatsu
- Department of Obstetrics and GynecologyNational Cerebral and Cardiovascular CenterOsakaJapan
| | - H. Ueda
- Department of PathologyNational Cerebral and Cardiovascular CenterOsakaJapan
| | - K. Ogo
- Department of PathologyNational Cerebral and Cardiovascular CenterOsakaJapan
| | - P. Chaemsaithong
- Department of Obstetrics and GynaecologyPrince of Wales Hospital, The Chinese University of Hong KongShatinHong Kong SAR
| | - L. C. Poon
- Department of Obstetrics and GynaecologyPrince of Wales Hospital, The Chinese University of Hong KongShatinHong Kong SAR
| |
Collapse
|
27
|
Toh U, Okabe M, Takao Y, Tanaka Y, Shigaki T, Takenaka M, Iwakuma N, Sudo T, Yamada A, Shichijo S, Itoh K, Akagi Y. Abstract P4-06-06: Comparison of the immunological and clinical effect of personalized peptide vaccination for patients with breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-06-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Selected therapeutic personalized peptide vaccines (PPV) were effective for boosting anticancer immune response that was associated with the clinical outcome as a prognostic factor for metastatic recurrent breast cancer (mrBC) 1-2. In this study, we investigated the immunological and clinical effect of PPV as the prophylactic cancer vaccine for non-recurrent but high-risk BC (nrhrBC) patients (pts), and we compared it's features to those of the mrBC pts who had active cancers or became resistant to the standard therapies(TR-mrBC). Methods: Material and Patient eligibility criteria: The peptides were selected from the 31 PPVs according to the results of HLA typing and peptide-specific IgG titers. Pts with a histological diagnosis of BC and their HLA-A molecules should be each of -A2, A3, A11, A24, A26, A31 or A33. The clinical protocols were approved by the institutional review board. (UMIN000003081and 00000184400000). Treatment schedule: A maximum of 4 peptides was administrated as weekly for initial four vaccinations and as biweekly for further inoculations. The concomitant standard endocrine therapy and the chemo-endocrine therapy were available for nrhrBC pts after finishing the standard adjuvant chemotherapy, and for mrBC pts concurrently. Immune and clinical response assessment: Specific T-cell responses, IgG titers and cytokines were evaluated using by interferon (IFN)-γ ELISPOT, Luminex assay and ELISA system in every 6-8 vaccinations. Toxicity, clinical response and correlation with the immune responses were investigated. Results: 16 pts with nrhrBC, 41 pts with mrBC and 79 pts with TR-mrBC received median 18, 16 and 14 vaccines, respectively. After PPV therapies, peptide-specific IgG and CTLs increased significantly in a total of 47 (77%) and 37(60%) in nrhrBC pts, 102 (63%) and 98 (61%) in mrBC pts, and 150(53%) and 100 (42%) in TR-mrBC pts. Pts experienced Grade 1-3 skin reaction at injection site, no other grade 3 or 4 SAEs were associated with PPV but with the disease progression or combination therapy. The median time to progression (TTP) and overall survival (OS) were not reached in nrhrBC pts, 7.8 and 29 months in mrBC pts, and were 7.5 and 15.9 months in TR-mrBC pts, respectively. The peptide specific CTL response was correlated significantly with OS in nrhrBC pts and the IgG levels were associated with the better OS in either non TR-mrBC pts or TR-mrBC pts. High levels of IL-6, GM-CSF, IFN-g, IL-2 receptor, BAFF were associated with worse prognosis for pts with TR-mrBC. And high levels of GM-CSF and BAFF were associated with worse prognosis for pts with nrhrBC and mrBC, respectively. In contrast, High levels of IL-2 were associated with the better prognosis for pts with mrBC. Conclusion: This study indicated that immunological features of these three groups were different from each other with most potent PPV-induced immune boosting for nrhrBC pts. Pts with mrBC who had lower immune-suppressive cytokine levels had the better prognosis. These results suggested the PPV therapy could be effective for postoperative prophylactic vaccination in patients with nrhrBC. References: 1. Takahashi R, Toh U, et al. Breast Cancer Res. 2014; 2. Toh U, Okabe M, et al. THE BREAST 2015.
Citation Format: Toh U, Okabe M, Takao Y, Tanaka Y, Shigaki T, Takenaka M, Iwakuma N, Sudo T, Yamada A, Shichijo S, Itoh K, Akagi Y. Comparison of the immunological and clinical effect of personalized peptide vaccination for patients with breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-06-06.
Collapse
Affiliation(s)
- U Toh
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - M Okabe
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - Y Takao
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - Y Tanaka
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - T Shigaki
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - M Takenaka
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - N Iwakuma
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - T Sudo
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - A Yamada
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - S Shichijo
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - K Itoh
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - Y Akagi
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| |
Collapse
|
28
|
Ishihara S, Okada S, Ogi H, Kodama Y, Itoh K, Marx A, Inoue M. P1.14-11 The Expression Pattern of Programmed Death-Ligand 1 According to the Pathological Type of Malignant Thymic Epithelial Tumors. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
29
|
Hosoya M, Kobayashi R, Ishii T, Senarita M, Kuroda H, Misawa H, Tanaka F, Takiguchi T, Tashiro M, Masuda S, Hashimoto S, Goto F, Minami S, Yamamoto N, Nagai R, Sayama A, Wakabayashi T, Toshikuni K, Ueha R, Fujimaki Y, Takazawa M, Sekimoto S, Itoh K, Nito T, Kada A, Tsunoda K. Vocal Hygiene Education Program Reduces Surgical Interventions for Benign Vocal Fold Lesions: A Randomized Controlled Trial. Laryngoscope 2018; 128:2593-2599. [PMID: 30079962 PMCID: PMC6585860 DOI: 10.1002/lary.27415] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Revised: 04/22/2018] [Accepted: 06/05/2018] [Indexed: 11/29/2022]
Abstract
Objectives/Hypothesis Vocal fold polyps and nodules are common benign laryngeal lesions. Currently, the Japanese health insurance system covers surgical interventions. However, the establishment of more cost‐effective conservative methods is required, because healthcare costs are viewed as a major concern, and the government and taxpayers are demanding more economical, effective treatments. In this situation, more suitable vocal hygiene education may be important for the success of cost‐effective conservative treatment. In this study, we developed a novel reinforced vocal hygiene education program and compared the results of this program with those of previous methods of teaching vocal hygiene. Study Design Multicenter randomized controlled trial. Methods Patients who visited a National Hospital Organization (NHO) hospital for the surgical indication of hoarseness were included in the study. Before undergoing surgery, 200 patients with benign vocal fold lesions (vocal fold polyps/nodules) were enrolled and randomly allocated to the NHO‐style vocal hygiene educational program (intervention group) or control education program (control group). Two months after enrollment, the patients in both groups underwent laryngeal fiberscopic examinations to determine whether the benign lesions had resolved or whether surgery was indicated for the vocal fold polyps/nodules. Results After 2 months, in the intervention group, the proportion of lesion resolution (61.3%) was significantly greater than that in the control group (26.3%) (P < .001, Fisher exact test). Conclusions Our results clearly indicate that the quality and features of the education program could affect the outcome of the intervention. We found that a reinforced vocal hygiene education program increased the rate of the resolution of benign vocal fold polyps and nodules in a multicenter randomized clinical trial. Level of Evidence 1b Laryngoscope, 2593–2599, 2018
Collapse
Affiliation(s)
- Makoto Hosoya
- Department of Otolaryngology, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan.,Clinical Research Center, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
| | - Rika Kobayashi
- Clinical Research Center, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan.,Department of Artificial Organs and Medical Creation, National Institute of Sensory Organs, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
| | - Toyota Ishii
- Department of Otolaryngology, National Hospital Organization, Sagamihara Hospital Organization, Sagamihara, Japan
| | - Masamitsu Senarita
- Department of Otolaryngology, National Hospital Organization, Mito Medical Center, Mito, Japan
| | - Hiroyuki Kuroda
- Department of Otolaryngology, National Hospital Organization, Kobe Medical Center, Kobe, Japan
| | - Hayato Misawa
- Department of Otolaryngology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
| | - Fujinobu Tanaka
- Department of Otolaryngology, National Hospital Organization, Nagasaki Medical Center, Nagasaki, Japan
| | - Tetsuya Takiguchi
- Department of Otolaryngology, National Hospital Organization, Kanazawa Medical Center, Kanazawa, Japan
| | - Masatsugu Tashiro
- Department of Otolaryngology, National Hospital Organization, Tochigi Medical Center, Tochigi, Japan
| | - Sawako Masuda
- Department of Otolaryngology, Mie National Hospital, Tsu, Japan
| | - Sho Hashimoto
- Department of Otolaryngology, National Hospital Organization, Sendai Medical Center, Sendai, Japan
| | - Fumiyuki Goto
- Department of Otolaryngology, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan.,National Institute of Sensory Organs, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
| | - Shujiro Minami
- Department of Otolaryngology, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
| | - Nobuko Yamamoto
- Department of Otolaryngology, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
| | - Ryoto Nagai
- Department of Otolaryngology, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
| | - Akiko Sayama
- Department of Otolaryngology, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
| | - Takeshi Wakabayashi
- Department of Otolaryngology, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
| | - Keitaro Toshikuni
- Department of Otolaryngology, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
| | - Rumi Ueha
- Department of Otolaryngology, University of Tokyo Hospital, Tokyo, Japan
| | - Yoko Fujimaki
- Department of Otolaryngology, University of Tokyo Hospital, Tokyo, Japan
| | - Mihiro Takazawa
- Department of Artificial Organs and Medical Creation, National Institute of Sensory Organs, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
| | - Sotaro Sekimoto
- Department of Artificial Organs and Medical Creation, National Institute of Sensory Organs, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
| | - Kenji Itoh
- Department of Artificial Organs and Medical Creation, National Institute of Sensory Organs, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
| | - Takaharu Nito
- Department of Otolaryngology, University of Tokyo Hospital, Tokyo, Japan
| | - Akiko Kada
- Clinical Research Center, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
| | - Koichi Tsunoda
- Department of Otolaryngology, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan.,Clinical Research Center, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan.,Department of Artificial Organs and Medical Creation, National Institute of Sensory Organs, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan.,Department of Otolaryngology, University of Tokyo Hospital, Tokyo, Japan
| |
Collapse
|
30
|
Tominaga K, Uchida T, Imakiire T, Itoh K, Shimazaki H, Nakanishi K, Kumagai H, Oshima N. Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A 2 receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis. BMC Nephrol 2018; 19:120. [PMID: 29792176 PMCID: PMC5966893 DOI: 10.1186/s12882-018-0922-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2017] [Accepted: 05/16/2018] [Indexed: 11/23/2022] Open
Abstract
Background Podocyte phospholipase A2 receptor (PLA2R) is a major target antigen in idiopathic adult membranous nephropathy (MN). Histological PLA2R staining in the renal tissue has proven to be useful for the detection of idiopathic MN. However, glomerular PLA2R deposits have also been recently observed in several patients with secondary MN, such as hepatitis B virus-associated, hepatitis C virus-associated, and neoplasm-associated MN. Certain inflammatory environments have been suggested to lead to abnormal expression of PLA2R epitopes, with the resulting production of PLA2R autoantibodies. Case presentation We report two patients diagnosed with anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis with MN-lesions, in whom ANCA titers for myeloperoxidase (MPO) were persistently positive. The first patient was a 52-years-old man who presented with interstitial pneumonitis. Microscopic hematuria and proteinuria were found when the interstitial pneumonitis became more severe. Renal biopsy findings yielded a diagnosis of ANCA-associated glomerulonephritis (mixed class) with MN-lesions. The second patient was a 63-years-old woman who had been treated for relapsing polychondritis. Her renal tissue showed evidence of focal ANCA-associated glomerulonephritis with MN-lesions. Interestingly, both MPO and PLA2R were detected in the glomerular subepithelial deposits of both patients. Immunoglobulin G (IgG) 1 and IgG2 were positive in the glomeruli of patient 2, and all subclasses of IgGs were positive in patient 1. Conclusion The present cases suggest that ANCA-associated glomerulonephritis could expose PLA2R, leading to the development of MN-lesions.
Collapse
Affiliation(s)
- Kenta Tominaga
- Department of Nephrology and Endocrinology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
| | - Takahiro Uchida
- Department of Nephrology and Endocrinology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Toshihiko Imakiire
- Department of Nephrology and Endocrinology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Kenji Itoh
- Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Hideyuki Shimazaki
- Department of Laboratory Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Kuniaki Nakanishi
- Department of Laboratory Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Hiroo Kumagai
- Department of Nephrology and Endocrinology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Naoki Oshima
- Department of Nephrology and Endocrinology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| |
Collapse
|
31
|
Oka Y, Itoh K, Takata N. 0824 Sleep Habit Among Preschoolers: Comparison Between Children Attending Kindergartens and Nursery Schools. Sleep 2018. [DOI: 10.1093/sleep/zsy061.823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Y Oka
- Center for Sleep Medicine, Ehime University Hospital, Ehime, JAPAN
| | - K Itoh
- Ube Frontier College, Yamaguchi, JAPAN
| | - N Takata
- School of Nursing, Shikoku University, Tokushima, JAPAN
| |
Collapse
|
32
|
Hirose W, Harigai M, Uchiyama T, Itoh K, Ishizuka T, Matsumoto M, Nanki T. Low body mass index and lymphocytopenia associate with Mycobacterium avium complex pulmonary disease in patients with rheumatoid arthritis. Mod Rheumatol 2018. [DOI: 10.1080/14397595.2018.1452334] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Affiliation(s)
| | - Masayoshi Harigai
- Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| | - Takashi Uchiyama
- Division of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Society, Tokyo, Japan
| | - Kenji Itoh
- Department of Internal Medicine, Division of Rheumatology, National Defense Medical College, Saitama, Japan
| | - Toshiaki Ishizuka
- Department of Pharmacology, National Defense Medical College, Saitama, Japan
| | | | - Toshihiro Nanki
- Department of Internal Medicine, Division of Rheumatology, Toho University School of Medicine, Tokyo, Japan
| |
Collapse
|
33
|
Toh U, Saku S, Iwakuma N, Takao Y, Okabe M, Akashi M, Yamada A, Shichijo S, Itoh K, Akagi Y. Abstract P3-05-09: Prognostic factors for therapeutic personalized peptide vaccines in patients with metastatic recurrent breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-05-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: We have previously reported the prognostic role of humoral antigen spreading response against prostate-related antigen (PRA) for metastatic recurrent breast cancer (mrBC) patients who received personalized peptide vaccine (PPV) therapy (Toh U, SABCS 2015). The prognostic effect was additionally evaluated by the clinical relevant factors including intrinsic subtype, the regimens of combined chemo-hormonal therapies in present study.
Methods:We analyzed serum IgG responses to all of the peptide candidates included PRAs (PSA, PAP and PMSA) after PPV therapy by the Luminex systemusing peripheral blood samples from 77 vaccinated mrBC patients. The clinical factors and relevant events were statistically evaluated.
Results: After 6 and 12cycles of PPV therapy, the serum IgG of anti-PSA, anti-PAP, and/or anti-PMSA increased significantly in 31 patients (PRA response group), and the median progression free survival (PFS) and median overall survival (OS) were 8.1 and 14.3 months, but were 5.1 and 10.8 months, respectively, in the remaining 46 patients with no anti-PRA IgG response (PRA non-response Group). The anti-PRA IgG level was marginally correlated withPFS (p=0.059) and OS (p=0.082) between these two groups, which was a significant prognostic factor for PFS (Log-rank: 0.009) in estrogen-positive cancer patients (ER+). The statistical analyses showed that the clinical outcome was in favor of > 60 year-old patients, those with longer PPV therapies (>3 months), and those who received combined standard hormonal therapies or bisphosphonate/anti-RANKL therapy.
Conclusions: This study indicated a clinical significance between the pre-and post- PPV therapy measurement of serum anti-PRA IgG in patients with mrBC, which may be a useful prognostic marker for monitoring peptide vaccine treatment outcomes, particularly for patients > 60 years with ER+ breast cancer. These results also suggest that the immunotherapeutic peptide vaccine could be efficiently combined with hormonal therapy, anti-HER2 therapy, and bisphosphonate/anti-RANKL therapy in mrBC patients.
Citation Format: Toh U, Saku S, Iwakuma N, Takao Y, Okabe M, Akashi M, Yamada A, Shichijo S, Itoh K, Akagi Y. Prognostic factors for therapeutic personalized peptide vaccines in patients with metastatic recurrent breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-05-09.
Collapse
Affiliation(s)
- U Toh
- Kurume University School of Medicine, Kurume, Japan; Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka, Japan; Kurume University Cancer Vaccine Center, Kurume, Fukuoka, Japan
| | - S Saku
- Kurume University School of Medicine, Kurume, Japan; Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka, Japan; Kurume University Cancer Vaccine Center, Kurume, Fukuoka, Japan
| | - N Iwakuma
- Kurume University School of Medicine, Kurume, Japan; Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka, Japan; Kurume University Cancer Vaccine Center, Kurume, Fukuoka, Japan
| | - Y Takao
- Kurume University School of Medicine, Kurume, Japan; Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka, Japan; Kurume University Cancer Vaccine Center, Kurume, Fukuoka, Japan
| | - M Okabe
- Kurume University School of Medicine, Kurume, Japan; Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka, Japan; Kurume University Cancer Vaccine Center, Kurume, Fukuoka, Japan
| | - M Akashi
- Kurume University School of Medicine, Kurume, Japan; Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka, Japan; Kurume University Cancer Vaccine Center, Kurume, Fukuoka, Japan
| | - A Yamada
- Kurume University School of Medicine, Kurume, Japan; Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka, Japan; Kurume University Cancer Vaccine Center, Kurume, Fukuoka, Japan
| | - S Shichijo
- Kurume University School of Medicine, Kurume, Japan; Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka, Japan; Kurume University Cancer Vaccine Center, Kurume, Fukuoka, Japan
| | - K Itoh
- Kurume University School of Medicine, Kurume, Japan; Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka, Japan; Kurume University Cancer Vaccine Center, Kurume, Fukuoka, Japan
| | - Y Akagi
- Kurume University School of Medicine, Kurume, Japan; Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka, Japan; Kurume University Cancer Vaccine Center, Kurume, Fukuoka, Japan
| |
Collapse
|
34
|
Kobayashi T, Sasaki M, Ido T, Kamiya K, Miura Y, Nagashima Y, Ida K, Inagaki S, Fujisawa A, Itoh SI, Itoh K. Quantification of Turbulent Driving Forces for the Geodesic Acoustic Mode in the JFT-2M Tokamak. Phys Rev Lett 2018; 120:045002. [PMID: 29437414 DOI: 10.1103/physrevlett.120.045002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2017] [Revised: 11/29/2017] [Indexed: 06/08/2023]
Abstract
We investigate spatial structures of turbulence and turbulent transport modulated by the geodesic acoustic mode (GAM), from which the excitation mechanism of the GAM is discussed. The GAM is found to be predominantly excited through a localized Reynolds stress force, rather than the dynamic shearing force. The evaluated growth rate is larger than the linear damping coefficients and is on the same order of magnitude as the effective growth rate evaluated from time evolution in the GAM kinetic energy.
Collapse
Affiliation(s)
- T Kobayashi
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki 509-5292, Japan
| | - M Sasaki
- Research Institute for Applied Mechanics, Kyushu University, Kasuga 816-8580, Japan
- Research Center for Plasma Turbulence, Kyushu University, Kasuga 816-8580, Japan
| | - T Ido
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki 509-5292, Japan
| | - K Kamiya
- National Institutes for Quantum and Radiological Science and Technology, Naka 311-0193, Japan
| | - Y Miura
- Japan Atomic Energy Agency, Naka 311-0193, Japan
| | - Y Nagashima
- Research Institute for Applied Mechanics, Kyushu University, Kasuga 816-8580, Japan
- Research Center for Plasma Turbulence, Kyushu University, Kasuga 816-8580, Japan
| | - K Ida
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki 509-5292, Japan
- Research Center for Plasma Turbulence, Kyushu University, Kasuga 816-8580, Japan
| | - S Inagaki
- Research Institute for Applied Mechanics, Kyushu University, Kasuga 816-8580, Japan
- Research Center for Plasma Turbulence, Kyushu University, Kasuga 816-8580, Japan
| | - A Fujisawa
- Research Institute for Applied Mechanics, Kyushu University, Kasuga 816-8580, Japan
- Research Center for Plasma Turbulence, Kyushu University, Kasuga 816-8580, Japan
| | - S-I Itoh
- Research Institute for Applied Mechanics, Kyushu University, Kasuga 816-8580, Japan
- Research Center for Plasma Turbulence, Kyushu University, Kasuga 816-8580, Japan
| | - K Itoh
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki 509-5292, Japan
- Research Center for Plasma Turbulence, Kyushu University, Kasuga 816-8580, Japan
- Institute of Science and Technology Research, Chubu University, Kasugai 487-8501, Japan
| |
Collapse
|
35
|
Abstract
OBJECTIVES This study from Japan extracted performance measures for dialysis unit management and investigated their characteristics from professional views. METHODS Two surveys were conducted using self-administered questionnaires, in which dialysis managers/staff were asked to rate the usefulness of 44 performance indicators. A total of 255 managers and 2,097 staff responded. RESULTS Eight performance measures were elicited from dialysis manager and staff responses: these were safety, operational efficiency, quality of working life, financial effectiveness, employee development, mortality, patient/employee satisfaction and patient-centred health care. These performance measures were almost compatible with those extracted in overall healthcare settings in a previous study. Internal reliability, content and construct validity of the performance measures for the dialysis setting were ensured to some extent. As a general trend, both dialysis managers and staff perceived performance measures as highly useful, especially for safety, mortality, operational efficiency and patient/employee satisfaction, but showed relatively low concerns for patient-centred health care and employee development. However, dialysis managers' usefulness perceptions were significantly higher than staff. CONCLUSIONS Important guidelines for designing a holistic hospital/clinic management system were yielded. Performance measures must be balanced for outcomes and performance shaping factors (PSF); a common set of performance measures could be applied to all the healthcare settings, although performance indicators of each measure should be composed based on the application field and setting; in addition, sound causal relationships between PSF and outcome measures/indicators should be explored for further improvement.
Collapse
Affiliation(s)
- Xiuzhu Gu
- Department of Industrial Engineering and Economics, Tokyo Institute of Technology, School of Engineering, Tokyo, Japan
| | - Kenji Itoh
- Department of Industrial Engineering and Economics, Tokyo Institute of Technology, School of Engineering, Tokyo, Japan
| |
Collapse
|
36
|
Shimozawa M, Hashimoto K, Ueda A, Suzuki Y, Sugii K, Yamada S, Imai Y, Kobayashi R, Itoh K, Iguchi S, Naka M, Ishihara S, Mori H, Sasaki T, Yamashita M. Quantum-disordered state of magnetic and electric dipoles in an organic Mott system. Nat Commun 2017; 8:1821. [PMID: 29180819 PMCID: PMC5703743 DOI: 10.1038/s41467-017-01849-x] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Accepted: 10/18/2017] [Indexed: 11/24/2022] Open
Abstract
Strongly enhanced quantum fluctuations often lead to a rich variety of quantum-disordered states. Developing approaches to enhance quantum fluctuations may open paths to realize even more fascinating quantum states. Here, we demonstrate that a coupling of localized spins with the zero-point motion of hydrogen atoms, that is, proton fluctuations in a hydrogen-bonded organic Mott insulator provides a different class of quantum spin liquids (QSLs). We find that divergent dielectric behavior associated with the approach to hydrogen-bond order is suppressed by the quantum proton fluctuations, resulting in a quantum paraelectric (QPE) state. Furthermore, our thermal-transport measurements reveal that a QSL state with gapless spin excitations rapidly emerges upon entering the QPE state. These findings indicate that the quantum proton fluctuations give rise to a QSL—a quantum-disordered state of magnetic and electric dipoles—through the coupling between the electron and proton degrees of freedom. The organic material κ-H3(Cat-EDT-TTF)2 has been suggested to exhibit a quantum spin liquid phase in which quantum fluctuations prevent the formation of magnetic order. Here, the authors show that this may be a result of fluctuations of hydrogen atoms, rather than more conventional geometric frustration.
Collapse
Affiliation(s)
- M Shimozawa
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan.
| | - K Hashimoto
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai, 980-8577, Japan.
| | - A Ueda
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - Y Suzuki
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - K Sugii
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - S Yamada
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - Y Imai
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - R Kobayashi
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai, 980-8577, Japan
| | - K Itoh
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai, 980-8577, Japan
| | - S Iguchi
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai, 980-8577, Japan
| | - M Naka
- Department of Physics, Tohoku University, Sendai, 980-8578, Japan.,Waseda Institute for Advanced Study, Waseda University, Shinjuku, Tokyo, 169-8050, Japan
| | - S Ishihara
- Department of Physics, Tohoku University, Sendai, 980-8578, Japan
| | - H Mori
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - T Sasaki
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai, 980-8577, Japan
| | - M Yamashita
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| |
Collapse
|
37
|
Kobayashi T, Itoh K, Ido T, Kamiya K, Itoh SI, Miura Y, Nagashima Y, Fujisawa A, Inagaki S, Ida K. Turbulent transport reduction induced by transition on radial electric field shear and curvature through amplitude and cross-phase in torus plasma. Sci Rep 2017; 7:14971. [PMID: 29097702 PMCID: PMC5668279 DOI: 10.1038/s41598-017-14821-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2017] [Accepted: 10/16/2017] [Indexed: 11/23/2022] Open
Abstract
Spatiotemporal evolutions of radial electric field and turbulence are measured simultaneously in the H-mode transition, which is a prototypical example of turbulence structure formation in high-temperature plasmas. In the dynamical phase where transport barrier is established abruptly, the time-space-frequency-resolved turbulent particle flux is obtained. Here we report the validation of the mechanism of transport barrier formation quantitatively. It is found that the particle flux is suppressed predominantly by reducing density fluctuation amplitude and cross phase between density fluctuation and potential fluctuation. Both radial electric field shear and curvature are responsible for the amplitude suppression as was predicted by theory. Turbulence amplitude reduction immediately responds to the growth of the radial electric field non-uniformity and saturates, while cross phase continuously approaches zero.
Collapse
Affiliation(s)
- T Kobayashi
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, 509-5292, Japan.
| | - K Itoh
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, 509-5292, Japan.,Institute of Science and Technology Research, Chubu University, Kasugai, 487-8501, Japan.,Research Center for Plasma Turbulence, Kyushu University, Kasuga, 816-8580, Japan
| | - T Ido
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, 509-5292, Japan
| | - K Kamiya
- National Institute for Quantum and Radiological Science and Technology, Naka, 311-0193, Japan
| | - S-I Itoh
- Research Center for Plasma Turbulence, Kyushu University, Kasuga, 816-8580, Japan.,Research Institute for Applied Mechanics, Kyushu University, Kasuga, 816-8580, Japan
| | - Y Miura
- Japan Atomic Energy Agency, Tokai, 319-1184, Japan
| | - Y Nagashima
- Research Center for Plasma Turbulence, Kyushu University, Kasuga, 816-8580, Japan.,Research Institute for Applied Mechanics, Kyushu University, Kasuga, 816-8580, Japan
| | - A Fujisawa
- Research Center for Plasma Turbulence, Kyushu University, Kasuga, 816-8580, Japan.,Research Institute for Applied Mechanics, Kyushu University, Kasuga, 816-8580, Japan
| | - S Inagaki
- Research Center for Plasma Turbulence, Kyushu University, Kasuga, 816-8580, Japan.,Research Institute for Applied Mechanics, Kyushu University, Kasuga, 816-8580, Japan
| | - K Ida
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, 509-5292, Japan.,Research Center for Plasma Turbulence, Kyushu University, Kasuga, 816-8580, Japan
| |
Collapse
|
38
|
Shindo A, Maki T, Egawa N, Liang A, Itoh K, Lo E, Arai K, Tomimoto H. Pentraxin 3 supports blood-brain barrier integrity after ischemic stroke. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
39
|
Sasaki S, Hashimoto K, Kobayashi R, Itoh K, Iguchi S, Nishio Y, Ikemoto Y, Moriwaki T, Yoneyama N, Watanabe M, Ueda A, Mori H, Kobayashi K, Kumai R, Murakami Y, Müller J, Sasaki T. Crystallization and vitrification of electrons in a glass-forming charge liquid. Science 2017; 357:1381-1385. [PMID: 28963251 DOI: 10.1126/science.aal3120] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Accepted: 08/23/2017] [Indexed: 11/03/2022]
Abstract
Charge ordering (CO) is a phenomenon in which electrons in solids crystallize into a periodic pattern of charge-rich and charge-poor sites owing to strong electron correlations. This usually results in long-range order. In geometrically frustrated systems, however, a glassy electronic state without long-range CO has been observed. We found that a charge-ordered organic material with an isosceles triangular lattice shows charge dynamics associated with crystallization and vitrification of electrons, which can be understood in the context of an energy landscape arising from the degeneracy of various CO patterns. The dynamics suggest that the same nucleation and growth processes that characterize conventional glass-forming liquids guide the crystallization of electrons. These similarities may provide insight into our understanding of the liquid-glass transition.
Collapse
Affiliation(s)
- S Sasaki
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai 980-8577, Japan.
| | - K Hashimoto
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai 980-8577, Japan.
| | - R Kobayashi
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai 980-8577, Japan.
| | - K Itoh
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai 980-8577, Japan.
| | - S Iguchi
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai 980-8577, Japan.
| | - Y Nishio
- Department of Physics, Faculty of Science, Toho University, Funabashi, Chiba 274-8510, Japan.
| | - Y Ikemoto
- Japan Synchrotron Radiation Research Institute, SPring-8, Sayo, Hyogo 679-5198, Japan.
| | - T Moriwaki
- Japan Synchrotron Radiation Research Institute, SPring-8, Sayo, Hyogo 679-5198, Japan.
| | - N Yoneyama
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai 980-8577, Japan
| | - M Watanabe
- Department of Physics, Faculty of Science, Toho University, Funabashi, Chiba 274-8510, Japan
| | - A Ueda
- Japan Synchrotron Radiation Research Institute, SPring-8, Sayo, Hyogo 679-5198, Japan
| | - H Mori
- Japan Synchrotron Radiation Research Institute, SPring-8, Sayo, Hyogo 679-5198, Japan
| | - K Kobayashi
- CMRC and Photon Factory, Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - R Kumai
- Graduate Faculty of Interdisciplinary Research, University of Yamanashi, Kohu, Yamanashi 400-8511, Japan
| | - Y Murakami
- Graduate Faculty of Interdisciplinary Research, University of Yamanashi, Kohu, Yamanashi 400-8511, Japan
| | - J Müller
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Sendai 980-8577, Japan
| | - T Sasaki
- Institute for Materials Research, Tohoku University, Aoba-ku, Sendai 980-8577, Japan.
| |
Collapse
|
40
|
Hirai K, Shirai T, Suzuki M, Akamatsu T, Suzuki T, Hayashi I, Yamamoto A, Akita T, Morita S, Asada K, Tsuji D, Inoue K, Itoh K. A clustering approach to identify and characterize the asthma and chronic obstructive pulmonary disease overlap phenotype. Clin Exp Allergy 2017; 47:1374-1382. [PMID: 28658564 DOI: 10.1111/cea.12970] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2017] [Revised: 06/05/2017] [Accepted: 06/22/2017] [Indexed: 12/20/2022]
Abstract
BACKGROUND Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous diseases. The phenotypes that have clinical features of both asthma and COPD are still incompletely understood. OBJECTIVE To clarify the best discriminators of the asthma-COPD overlap phenotype from asthma and COPD subgroups using a clustering approach. METHODS This study assessed pathophysiological parameters, including mRNA expression levels of T helper cell-related transcription factors, namely TBX21 (Th1), GATA3 (Th2), RORC (Th17) and FOXP3 (Treg), in peripheral blood mononuclear cells in asthma patients (n=152) and in COPD patients (n=50). Clusters were determined using k-means clustering. Exacerbations of asthma and COPD were recorded during the 1-year follow-up period. RESULTS The cluster analysis revealed four biological clusters: cluster 1, predominantly patients with COPD; cluster 2, patients with an asthma-COPD overlap phenotype; cluster 3, patients with non-atopic and late-onset asthma; and cluster 4, patients with early-onset atopic asthma. Hazard ratios for exacerbation were 2.5 (95% confidence interval [CI], 1.1-5.6) in cluster 1 and 2.3 (95% CI, 1.0-5.0) in cluster 2 compared with patients in other clusters. Cluster 2 was discriminated from other clusters by total serum IgE level ≥310 IU/mL, blood eosinophil counts ≥280 cells/μL, a higher ratio of TBX21/GATA3, FEV1 /FVC ratio <0.67 and smoking ≥10 pack-years with an area under the curve of 0.94 (95% CI, 0.90-0.98) in the receiver operating characteristic analysis. CONCLUSIONS AND CLINICAL RELEVANCE The asthma-COPD overlap phenotype was characterized by peripheral blood eosinophilia and higher levels of IgE despite the Th2-low endotype.
Collapse
Affiliation(s)
- K Hirai
- Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.,Laboratory of Clinical Pharmacogenomics, Shizuoka General Hospital, Shizuoka, Japan
| | - T Shirai
- Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan
| | - M Suzuki
- Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
| | - T Akamatsu
- Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan
| | - T Suzuki
- Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan
| | - I Hayashi
- Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan
| | - A Yamamoto
- Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan
| | - T Akita
- Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan
| | - S Morita
- Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan
| | - K Asada
- Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan
| | - D Tsuji
- Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.,Laboratory of Clinical Pharmacogenomics, Shizuoka General Hospital, Shizuoka, Japan
| | - K Inoue
- Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.,Laboratory of Clinical Pharmacogenomics, Shizuoka General Hospital, Shizuoka, Japan
| | - K Itoh
- Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.,Laboratory of Clinical Pharmacogenomics, Shizuoka General Hospital, Shizuoka, Japan
| |
Collapse
|
41
|
Furukawa M, Sakakibara T, Itoh K, Kawamura K, Matsuura M, Kojima H. Suggestion of the updated IVIS cut-off values for identifying non-ocular irritants in the bovine corneal opacity and permeability (BCOP) assay. Toxicol In Vitro 2017; 45:19-24. [PMID: 28765095 DOI: 10.1016/j.tiv.2017.07.026] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Revised: 06/09/2017] [Accepted: 07/27/2017] [Indexed: 10/19/2022]
Abstract
The bovine corneal opacity and permeability (BCOP) assay is an alternative to the Draize test in rabbits. Although it can be used to evaluate ocular non-irritants and severe irritants, it is not used for the assessment of mild-irritating substances. In this assay, a chemical with an in vitro irritancy score (IVIS)≤3 is defined as a "non-irritant" while one with an IVIS>55 is defined as a "corrosive" or "severe irritant." We attempted to evaluate mild eye irritants by assessing the recovery of corneal lesions histopathologically. Our results indicated that chemicals with IVIS≤6 may be defined as "non-irritants," because the rapid recovery of lesions limited to the squamous layer was predicted by the histopathology. In cases where lesions extended to the wing and basal cell layers, when some intact basal cells remained, the lesions were also predicted to be reversible. Thus, chemicals which induce lesions in which basal cells remain intact can be considered to be mild irritants.
Collapse
Affiliation(s)
- M Furukawa
- Safety Research Institute for Chemical Compounds Co., Ltd., 363-24 Shin-ei, Kiyotaa-ku, Sapporo, Hokkaido 004-0839, Japan.
| | - T Sakakibara
- Safety Research Institute for Chemical Compounds Co., Ltd., 363-24 Shin-ei, Kiyotaa-ku, Sapporo, Hokkaido 004-0839, Japan
| | - K Itoh
- Safety Research Institute for Chemical Compounds Co., Ltd., 363-24 Shin-ei, Kiyotaa-ku, Sapporo, Hokkaido 004-0839, Japan
| | - K Kawamura
- Safety Research Institute for Chemical Compounds Co., Ltd., 363-24 Shin-ei, Kiyotaa-ku, Sapporo, Hokkaido 004-0839, Japan
| | - M Matsuura
- Safety Research Institute for Chemical Compounds Co., Ltd., 363-24 Shin-ei, Kiyotaa-ku, Sapporo, Hokkaido 004-0839, Japan
| | - H Kojima
- National Institute of Health Science, 1-18-1 Kamiyoga, Setagaya, Tokyo 158-8501, Japan
| |
Collapse
|
42
|
Ueshima T, Yamaguchi T, Itoh K, Kashimoto N, Hirano T, Shimabara R, Kawakubo Y, Sato M, Yamashita J, Yazaki A, Tamura K. Abstract 5106: In vitro and in vivo evaluation of WAC-224, a novel quinolone class of topoisomerase II inhibitor for cancer therapy. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-5106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: DNA topoisomerases (Topo) are classical but still attractive targets for drug therapy in multiple types of cancers. Topo inhibitors, such as Etoposide and Daunorubicin, have been effectively used; however, their clinical use is often limited by drug resistance in cancer cell population. Therefore, the development of a novel chemical class of Topo inhibitors has been desired to overcome drug resistance. Recently, Vosaroxin (QINPREZO) is identified as a first-in-class anti-cancer quinolone derivative targeting Topo II, which is under development for relapsed or refractory acute myeloid leukemia (AML). In this study, we evaluated the in vitro and in vivo activities of WAC-224, a novel quinolone derivative for Topo II inhibition, for various cancer cell lines including multi-drug resistant cells and in mouse xenograft models, respectively.
Materials and Methods: In vitro anti-proliferative activities against over 20 cell lines were determined using WST cell proliferation reagent. Apoptosis was measured by Annexin-V staining. In vivo anti-tumor activity was determined in immunodeficient mice bearing multi-drug resistant human uterine sarcoma MES-SA/DX5.
Results: WAC-224 accomplished extensive anti-proliferative activities for cancer cell lines including multi-drug resistant ones with the EC50 range of 0.001 to 1 microM. Especially, in MV4-11 AML cell line, WAC-224 showed a potent and superior anti-proliferative activity compared with Doxorubicin (EC50: 1.4 nM for WAC-224 v.s. 2.5 nM for Doxorubicin). Molecular and cellular mechanisms of WAC-224 were defined as inhibition of human Topo II, induction of G2/M phase cell cycle arrest and apoptosis. Additionally, significant antitumor effects of WAC-224 were confirmed in mouse xenograft models. Furthermore, WAC-224 showed no toxic effect on small intestinal crypts in mice.
Conclusion: This study demonstrated that WAC-224 has strong in vitro activities against broad cancer cell types along with the potent in vivo efficacy and well tolerability, without gastrointestinal toxicity. These results indicate that WAC-224 is promised to provide a new therapeutic option for various cancers including multi-drug resistant and hematological ones.
Citation Format: Taichi Ueshima, Tomonori Yamaguchi, Kenji Itoh, Naoki Kashimoto, Tatsuya Hirano, Rumiko Shimabara, Yohei Kawakubo, Masayuki Sato, Junpei Yamashita, Akira Yazaki, Koichi Tamura. In vitro and in vivo evaluation of WAC-224, a novel quinolone class of topoisomerase II inhibitor for cancer therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5106. doi:10.1158/1538-7445.AM2017-5106
Collapse
Affiliation(s)
- Taichi Ueshima
- Wakunaga Pharmaceutical Co., Ltd, Akitakata-shi, Hiroshima, Japan
| | | | - Kenji Itoh
- Wakunaga Pharmaceutical Co., Ltd, Akitakata-shi, Hiroshima, Japan
| | - Naoki Kashimoto
- Wakunaga Pharmaceutical Co., Ltd, Akitakata-shi, Hiroshima, Japan
| | - Tatsuya Hirano
- Wakunaga Pharmaceutical Co., Ltd, Akitakata-shi, Hiroshima, Japan
| | - Rumiko Shimabara
- Wakunaga Pharmaceutical Co., Ltd, Akitakata-shi, Hiroshima, Japan
| | - Yohei Kawakubo
- Wakunaga Pharmaceutical Co., Ltd, Akitakata-shi, Hiroshima, Japan
| | - Masayuki Sato
- Wakunaga Pharmaceutical Co., Ltd, Akitakata-shi, Hiroshima, Japan
| | - Junpei Yamashita
- Wakunaga Pharmaceutical Co., Ltd, Akitakata-shi, Hiroshima, Japan
| | - Akira Yazaki
- Wakunaga Pharmaceutical Co., Ltd, Akitakata-shi, Hiroshima, Japan
| | - Koichi Tamura
- Wakunaga Pharmaceutical Co., Ltd, Akitakata-shi, Hiroshima, Japan
| |
Collapse
|
43
|
Abstract
A calculation which describes the spin-up of toroidal plasmas by the radial propagation of turbulence fronts with broken parallel symmetry is presented. The associated flux of parallel momentum is calculated by using a two-scale direct-interaction approximation in the weak turbulence limit. We show that fluctuation momentum spreads faster than mean flow momentum. Specifically, the turbulent flux of wave momentum is stronger than the momentum pinch. The scattering of fluctuation momentum can induce edge-core coupling of toroidal flows, as observed in experiments.
Collapse
Affiliation(s)
- Y Kosuga
- Research Institute for Applied Mechanics, Kyushu University, Fukuoka, Japan.,Research Center for Plasma Turbulence, Kyushu University, Fukuoka, Japan
| | - S-I Itoh
- Research Institute for Applied Mechanics, Kyushu University, Fukuoka, Japan.,Research Center for Plasma Turbulence, Kyushu University, Fukuoka, Japan
| | - P H Diamond
- University of California, San Diego, La Jolla, California 92093, USA
| | - K Itoh
- Research Center for Plasma Turbulence, Kyushu University, Fukuoka, Japan.,National Institute for Fusion Science, Gifu, Japan
| |
Collapse
|
44
|
Komori A, Morisaki T, Mutoh T, Sakakibara S, Takeiri Y, Kumazawa R, Kubo S, Ida K, Morita S, Narihara K, Shimozuma T, Tanaka K, Watanabe KY, Yamada H, Yoshinuma M, Akiyama T, Ashikawa N, Emoto M, Funaba H, Goto M, Ido T, Ikeda K, Inagaki S, Isobe M, Igami H, Itoh K, Kaneko O, Kawahata K, Kobuchi T, Masuzaki S, Matsuoka K, Minami T, Miyazawa J, Muto S, Nagayama Y, Nakamura Y, Nakanishi H, Narushima Y, Nishimura K, Nishiura M, Nishizawa A, Noda N, Ohdachi S, Oka Y, Osakabe M, Ohyabu N, Ozaki T, Peterson BJ, Sagara A, Saito K, Sakamoto R, Sato K, Sato M, Seki T, Shoji M, Sudo S, Tamura N, Toi K, Tokuzawa T, Tsumori K, Uda T, Watari T, Yamada I, Yokoyama M, Yoshimura Y, Motojima O, Beidler CD, Fujita T, Isayama A, Sakamoto Y, Takenaga H, Goncharov P, Ishii K, Sakamoto M, Murakami S, Notake T, Takeuchi N, Okajima S, Sasao M. Overview of Progress in LHD Experiments. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1229] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A. Komori
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Sakakibara
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - R. Kumazawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Shimozuma
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Yoshinuma
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Akiyama
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Ashikawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Emoto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Ido
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Inagaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Isobe
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Igami
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Itoh
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Kawahata
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Kobuchi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Matsuoka
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Minami
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Muto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Nagayama
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Nakamura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Nakanishi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Narushima
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Nishimura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Nishiura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - A. Nishizawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Noda
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Ohdachi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Oka
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Ozaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - A. Sagara
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Saito
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Sato
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Sato
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Seki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Shoji
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Sudo
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Tamura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Toi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Tokuzawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Tsumori
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Uda
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Watari
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - I. Yamada
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - O. Motojima
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - C. D. Beidler
- Max-Planck Institut fuer Plasmaphysik, Greifswald D-17491, Germany
| | - T. Fujita
- Japan Atomic Energy Research Institute, Naka 311-0193, Japan
| | - A. Isayama
- Japan Atomic Energy Research Institute, Naka 311-0193, Japan
| | - Y. Sakamoto
- Japan Atomic Energy Research Institute, Naka 311-0193, Japan
| | - H. Takenaga
- Japan Atomic Energy Research Institute, Naka 311-0193, Japan
| | - P. Goncharov
- Graduate University for Advanced Studies, School of Mathematical and Physical Science Department of Fusion Science, Hayama 240-0193, Japan
| | - K. Ishii
- Kyushu University, Research Institute for Applied Mechanics Kasuga 816-8580, Japan
| | - M. Sakamoto
- Kyushu University, Research Institute for Applied Mechanics Kasuga 816-8580, Japan
| | - S. Murakami
- Kyoto University, Department of Nuclear Engineering, Kyoto 606-8501, Japan
| | - T. Notake
- Nagoya University, Department of Energy Engineering and Science Nagoya 464-8603, Japan
| | - N. Takeuchi
- Nagoya University, Department of Energy Engineering and Science Nagoya 464-8603, Japan
| | - S. Okajima
- Chubu University, Kasugai, Aichi 487-8501, Japan
| | - M. Sasao
- Tohoku University, Graduate School of Engineering, Sendai 980-8579, Japan
| | | |
Collapse
|
45
|
Tamura N, Inagaki S, Tokuzawa T, Michael C, Tanaka K, Ida K, Shimozuma T, Kubo S, Itoh K, Nagayama Y, Kawahata K, Sudo S, Komori A. Experimental Study on Nonlocality of Heat Transport in LHD. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a10799] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- N. Tamura
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
| | - S. Inagaki
- Research Institute for Applied Mechanics, Kyushu University, 6-1 Kasuga-kouen Kasuga Fukuoka 816-8580, Japan
| | - T. Tokuzawa
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, Hayama Miura-gun Kanagawa 240-0193, Japan
| | - C. Michael
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, Hayama Miura-gun Kanagawa 240-0193, Japan
| | - T. Shimozuma
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
| | - K. Itoh
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
| | - Y. Nagayama
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, Hayama Miura-gun Kanagawa 240-0193, Japan
| | - K. Kawahata
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, Hayama Miura-gun Kanagawa 240-0193, Japan
| | - S. Sudo
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, Hayama Miura-gun Kanagawa 240-0193, Japan
| | - A. Komori
- National Institute for Fusion Science, 322-6 Oroshi-cho Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, Hayama Miura-gun Kanagawa 240-0193, Japan
| | | |
Collapse
|
46
|
Motojima O, Yamada H, Komori A, Watanabe KY, Mutoh T, Takeiri Y, Ida K, Akiyama T, Asakura N, Ashikawa N, Chikaraishi H, Cooper WA, Emoto M, Fujita T, Fujiwara M, Funaba H, Goncharov P, Goto M, Hamada Y, Higashijima S, Hino T, Hoshino M, Ichimura M, Idei H, Ido T, Ikeda K, Imagawa S, Inagaki S, Isayama A, Isobe M, Itoh T, Itoh K, Kado S, Kalinina D, Kaneba T, Kaneko O, Kato D, Kato T, Kawahata K, Kawashima H, Kawazome H, Kobuchi T, Kondo K, Kubo S, Kumazawa R, Lyon JF, Maekawa R, Mase A, Masuzaki S, Mito T, Matsuoka K, Miura Y, Miyazawa J, More R, Morisaki T, Morita S, Murakami I, Murakami S, Mutoh S, Nagaoka K, Nagasaki K, Nagayama Y, Nakamura Y, Nakanishi H, Narihara K, Narushima Y, Nishimura H, Nishimura K, Nishiura M, Nishizawa A, Noda N, Notake T, Nozato H, Ohdachi S, Ohkubo K, Ohyabu N, Oyama N, Oka Y, Okada H, Osakabe M, Ozaki T, Peterson BJ, Sagara A, Saida T, Saito K, Sakakibara S, Sakamoto M, Sakamoto R, Sasao M, Sato K, Seki T, Shimozuma T, Shoji M, Sudo S, Takagi S, Takahashi Y, Takase Y, Takenaga H, Takeuchi N, Tamura N, Tanaka K, Tanaka M, Toi K, Takahata K, Tokuzawa T, Torii Y, Tsumori K, Watanabe F, Watanabe M, Watanabe T, Watari T, Yamada I, Yamada S, Yamaguchi T, Yamamoto S, Yamazaki K, Yanagi N, Yokoyama M, Yoshida N, Yoshimura S, Yoshimura Y, Yoshinuma M. Review on the Progress of the LHD Experiment. Fusion Science and Technology 2017. [DOI: 10.13182/fst04-a535] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- O. Motojima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Akiyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Asakura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Ashikawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Chikaraishi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - W. A. Cooper
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Emoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Fujita
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Fujiwara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - P. Goncharov
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Hamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Higashijima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Hino
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Hoshino
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Ichimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Idei
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Ido
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Imagawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Inagaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Isayama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Isobe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Itoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Itoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Kado
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - D. Kalinina
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kaneba
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - D. Kato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Kawahata
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Kawashima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Kawazome
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kobuchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Kondo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Kumazawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - J. F. Lyon
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Maekawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Mase
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Mito
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Matsuoka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Miura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. More
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - I. Murakami
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Murakami
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Mutoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nagaoka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nagasaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Nagayama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Nakamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nakanishi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Narushima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nishimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nishimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Nishiura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Nishizawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Noda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Notake
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nozato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Ohdachi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ohkubo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Oyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Oka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Okada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Ozaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Sagara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Saida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Saito
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Sakakibara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Sakamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Sasao
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Sato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Seki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Shimozuma
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Shoji
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Sudo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Takagi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takahashi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takase
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Takenaga
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Takeuchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Tamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Toi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Takahata
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Tokuzawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Torii
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Tsumori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - F. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Watari
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - I. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Yamaguchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yamamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Yamazaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Yanagi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Yoshida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yoshimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Yoshinuma
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| |
Collapse
|
47
|
Amano H, Kazamori D, Itoh K. Evaluation of the Effects of S-Allyl-L-cysteine, S-Methyl-L-cysteine, trans-S-1-Propenyl-L-cysteine, and Their N-Acetylated and S-Oxidized Metabolites on Human CYP Activities. Biol Pharm Bull 2017; 39:1701-1707. [PMID: 27725449 DOI: 10.1248/bpb.b16-00449] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Three major organosulfur compounds of aged garlic extract, S-allyl-L-cysteine (SAC), S-methyl-L-cysteine (SMC), and trans-S-1-propenyl-L-cysteine (S1PC), were examined for their effects on the activities of five major isoforms of human CYP enzymes: CYP1A2, 2C9, 2C19, 2D6, and 3A4. The metabolite formation from probe substrates for the CYP isoforms was examined in human liver microsomes in the presence of organosulfur compounds at 0.01-1 mM by using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. Allicin, a major component of garlic, inhibited CYP1A2 and CYP3A4 activity by 21-45% at 0.03 mM. In contrast, a CYP2C9-catalyzed reaction was enhanced by up to 1.9 times in the presence of allicin at 0.003-0.3 mM. SAC, SMC, and S1PC had no effect on the activities of the five isoforms, except that S1PC inhibited CYP3A4-catalyzed midazolam 1'-hydroxylation by 31% at 1 mM. The N-acetylated metabolites of the three compounds inhibited the activities of several isoforms to a varying degree at 1 mM. N-Acetyl-S-allyl-L-cysteine and N-acetyl-S-methyl-L-cysteine inhibited the reactions catalyzed by CYP2D6 and CYP1A2, by 19 and 26%, respectively, whereas trans-N-acetyl-S-1-propenyl-L-cysteine showed weak to moderate inhibition (19-49%) of CYP1A2, 2C19, 2D6, and 3A4 activities. On the other hand, both the N-acetylated and S-oxidized metabolites of SAC, SMC, and S1PC had little effect on the reactions catalyzed by the five isoforms. These results indicated that SAC, SMC, and S1PC have little potential to cause drug-drug interaction due to CYP inhibition or activation in vivo, as judged by their minimal effects (IC50>1 mM) on the activities of five major isoforms of human CYP in vitro.
Collapse
Affiliation(s)
- Hirotaka Amano
- Drug Discovery Laboratory, Wakunaga Pharmaceutical Co., Ltd
| | | | | |
Collapse
|
48
|
Itoh K, Tanaka H, Seki M. Eye-Movement Analysis of Track Monitoring Patterns of Night Train Operators: Effects of Geographic Knowledge and Fatigue. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/154193120004402721] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Track maintenance is one of the most critical activities for railway safety, particularly for high-speed trains. In maintaining tracks, a number of special purpose trains are used for materials transportation, inspection of the track and rails, construction and other purposes. These track maintenance trains are operated under stressful and changing conditions such as the lack of traffic signals and low visibility. Therefore, it is of great importance to investigate train operators' human factors for enhancement of their operation quality and reliability. The present paper particularly focuses on their geographic knowledge on driving area and fatigue by time course as such factors. Through task analysis using eye-tracking data recorded during performance of track inspection task, several analytical diagrams were produced: transition network of attention allocation, distribution of eye-gaze duration at each location on the ground and surroundings, and so forth. Based on these results, we examine the effects of the train operator's human factors on their cognitive and perceptual processes, and also discuss the operator's strategy for obstacle detection on the track.
Collapse
Affiliation(s)
- Kenji Itoh
- Tokyo Institute of Technology Tokyo, Japan
| | | | | |
Collapse
|
49
|
Abstract
The present paper proposes a method for analyzing viewers' cognitive attitudes to commercial films (CF) on TV based on the eye-movement recording (EMR) technique and scenario description of a CF. In this method, a scenario is described in a time-line transition of displaying CF ingredients in a scene. CF ingredients are classified into three groups in terms of involvement of advertised claims: direct claimed items, indirect claimed items and no-claim involved items. This classification allows us not only to provide with a framework for analyzing EMR data but also to estimate claimed quantity containing a CF. A viewer's EMR data during watching a CF is transcribed according to this scenario description scheme. His/her cognitive attitudes to a particular CF are analyzed mainly based on two attitudinal measurements that can be generated by the EMR transcription combined with the scenario description. One measurement, effective gaze ratio, is relating to how intensively a viewer watches a CF. The other measurement, claim perception ratio, is an index for estimating how well a viewer acquires claims or messages regarding an advertised product, service or organization from the commercial film. A series of experiments were carried out with four subjects to obtain their eye-movement data using an ASL 4000 tracking system. Each subject performed six CF-watching sessions each of which was conducted on a different day using the same sixteen commercial films. The proposed method was applied to the experimental data to analyze the viewer's cognitive patterns to CF's. The obtained cognitive attitudes are discussed from relations between their individual attributes such as watching style of CF's and daily TV watching hours. Based on these results, we mentioned some implications on design parameters of CF's such as frequency of changing scene, and effects of celebrity.
Collapse
Affiliation(s)
| | - Kenji Itoh
- Tokyo Institute of Technology Tokyo, Japan
| |
Collapse
|
50
|
Fujimaki Y, Tsunoda K, Kobayashi R, Tonghyo C, Tanaka F, Kuroda H, Numata T, Ishii T, Kuroda R, Masuda S, Hashimoto S, Misawa H, Shindo N, Mori T, Mori H, Uchiyama N, Kamei Y, Tanaka M, Hamaya H, Funatsuki S, Usui S, Ito I, Hamada K, Shindo A, Tokumaru Y, Morita Y, Ueha R, Nito T, Kikuta S, Sekimoto S, Kondo K, Sakamoto T, Itoh K, Yamasoba T, Matsumoto S. Independent exercise for glottal incompetence to improve vocal problems and prevent aspiration pneumonia in the elderly: a randomized controlled trial. Clin Rehabil 2016; 31:1049-1056. [PMID: 27742752 PMCID: PMC5524188 DOI: 10.1177/0269215516673208] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Objectives: To evaluate the effect of a self-controlled vocal exercise in elderly people with glottal closure insufficiency. Design: Parallel-arm, individual randomized controlled trial. Methods: Patients who visited one of 10 medical centers under the National Hospital Organization group in Japan for the first time, aged 60 years or older, complaining of aspiration or hoarseness, and endoscopically confirmed to have glottal closure insufficiency owing to vocal cord atrophy, were enrolled in this study. They were randomly assigned to an intervention or a control group. The patients of the intervention group were given guidance and a DVD about a self-controlled vocal exercise. The maximum phonation time which is a measure of glottal closure was evaluated, and the number of patients who developed pneumonia during the six months was compared between the two groups. Results: Of the 543 patients enrolled in this trial, 259 were allocated into the intervention group and 284 into the control; 60 of the intervention group and 75 of the control were not able to continue the trial. A total of 199 patients (age 73.9 ±7.25 years) in the intervention group and 209 (73.3 ±6.68 years) in the control completed the six-month trial. Intervention of the self-controlled vocal exercise extended the maximum phonation time significantly (p < 0.001). There were two hospitalizations for pneumonia in the intervention group and 18 in the control group, representing a significant difference (p < 0.001). Conclusion: The self-controlled vocal exercise allowed patients to achieve vocal cord adduction and improve glottal closure insufficiency, which reduced the rate of hospitalization for pneumonia significantly. ClinicalTrial.govIdentifier-UMIN000015567
Collapse
Affiliation(s)
- Yoko Fujimaki
- 1 Department of Artificial Organs and Medical Device Creation, National Institute of Sensory Organs, Tokyo, Japan.,2 Department of Otolaryngology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - Koichi Tsunoda
- 1 Department of Artificial Organs and Medical Device Creation, National Institute of Sensory Organs, Tokyo, Japan
| | - Rika Kobayashi
- 1 Department of Artificial Organs and Medical Device Creation, National Institute of Sensory Organs, Tokyo, Japan
| | - Chong Tonghyo
- 3 Department of General Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Fujinobu Tanaka
- 4 Department of Otolaryngology, National Hospital Organization Nagasaki Medical Center, Tokyo, Japan
| | - Hiroyuki Kuroda
- 5 Department of Otolaryngology, National Hospital Organization Kobe Medical Center, Tokyo, Japan
| | | | - Toyota Ishii
- 7 Department of Otolaryngology, Sagamihara National Hospital, Tokyo, Japan
| | - Reiko Kuroda
- 8 Department of Otolaryngology, Hirosaki National Hospital, Tokyo, Japan
| | - Sawako Masuda
- 9 Department of Otolaryngology, National Mie Hospital, Tokyo, Japan
| | - Sho Hashimoto
- 10 Department of Otolaryngology, National Sendai Medical Center, Tokyo, Japan
| | - Hayato Misawa
- 11 Department of Otolaryngology, National Hospital Organization Nagoya Medical Center, Tokyo, Japan
| | - Naoko Shindo
- 12 Department of Rehabilitation, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Takahiro Mori
- 3 Department of General Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Hiroko Mori
- 3 Department of General Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Naoki Uchiyama
- 3 Department of General Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Yuichirou Kamei
- 3 Department of General Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Masashi Tanaka
- 3 Department of General Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Hironobu Hamaya
- 3 Department of General Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Shingo Funatsuki
- 3 Department of General Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Satoko Usui
- 9 Department of Otolaryngology, National Mie Hospital, Tokyo, Japan
| | - Ikuno Ito
- 12 Department of Rehabilitation, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Kohei Hamada
- 12 Department of Rehabilitation, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Akihito Shindo
- 13 Department of Otolaryngology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Yutaka Tokumaru
- 13 Department of Otolaryngology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Yoko Morita
- 14 Department of Neurology National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Rumi Ueha
- 2 Department of Otolaryngology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - Takaharu Nito
- 2 Department of Otolaryngology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - Shu Kikuta
- 2 Department of Otolaryngology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - Sotaro Sekimoto
- 1 Department of Artificial Organs and Medical Device Creation, National Institute of Sensory Organs, Tokyo, Japan
| | - Kenji Kondo
- 2 Department of Otolaryngology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - Takashi Sakamoto
- 2 Department of Otolaryngology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - Kenji Itoh
- 1 Department of Artificial Organs and Medical Device Creation, National Institute of Sensory Organs, Tokyo, Japan
| | - Tatsuya Yamasoba
- 2 Department of Otolaryngology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - Sumio Matsumoto
- 1 Department of Artificial Organs and Medical Device Creation, National Institute of Sensory Organs, Tokyo, Japan
| | | |
Collapse
|